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The integration of therapeutic genes 
into the genomes of patient’s cells 
can promote long-term expression, 
which is beneficial in the treatment of 
many disorders. However, integration 
can cause insertional mutagenesis 
and lead to the emergence of severe 
adverse effects. This thesis aimed at 
developing a vector that could target 
integration into safe areas within the 
human genome. Through modifica-
tions introduced into lentivirus vec-
tors, intracellular protein delivery and 
increased integration at the aimed 
rDNA site was achieved. These find-
ings may advance safer gene therapy. 
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ABSTRACT  
 
Inherited disorders can be treated with gene therapy by correcting a disease-underlying 
mutation in a patient’s gene (genome editing), or by permanently adding a new functional 
copy of a missing or dysfunctional gene (integration). Therapeutic gene addition can be 
accomplished with the aid of integrating gene transfer vehicles, or vectors, such as those 
based on Human Immunodeficiency virus-1 (HIV-1). HIV-1 is converted into a vector by 
disarming it of all of its disease-causing and replication-enabling elements, so that the 
remaining particle is only able to transfer a desired genetic cargo into target cells and 
subsequently catalyse its integration into the cellular genome. However, gene integration is 
not always a benign event, as it can disrupt the natural functioning of cellular genes. A 
therapeutic gene integrated into non-optimal genomic areas can even lead to the 
development of new diseases, such as cancer. Therefore integrating vectors are preferable 
for use in ex vivo gene therapy, where there is a possibility to select favourably altered cells 
prior to returning them into the patient. This type of selection procedures can, however, be 
laborious to conduct and there are currently no vectors available that could promote 
transgene integration without an inherent risk for insertional mutagenesis and adverse 
effects. 
The aim of this study was to develop a safely integrating gene transfer vector for use in 
gene therapy. Vector development involved modifying the integrase protein of a HIV-1 
based lentiviral vector by fusing it to a targeting protein, I-PpoI. Integrase is responsible for 
transgene integration into the cellular chromatin. I-PpoI can naturally recognize and bind to 
sequences in the ribosomal DNA that are thought to be safe sites for transgene integration. 
To test the functionality of the generated integrase-I-PpoI fusion protein in an optimal 
setting, a packaging method was developed that enabled foreign protein inclusion into 
lentivirus vectors without requiring modifications to vector production. To test whether the 
developed method would have broader applicability for the cellular delivery of 
heterologous proteins, additional integrase fusion proteins were generated. The genomic 
distribution of vector integration sites was studied in cell cultures using LM-PCR and 
bioinformatics methods. The IN-I-PpoI fusion protein was found to increase vector 
integration into the predetermined ribosomal DNA locus. In addition, the modification 
introduced into HIV-1 vectors was shown to aid in the transduction of proteins with 
characteristic similar to those that are used for genome editing and targeted gene insertion. 
These results may advance the development of safer vectors that are needed in gene 
therapy to be able to treat different disorders without causing integration-related safety 
risks and undesired adverse effects.  
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TIIVISTELMÄ  
 
Perinnöllisiä sairauksia voidaan hoitaa geeniterapialla korjaamalla sairauden aiheuttajana 
oleva viallinen geeni ns. genomin editoinnilla tai lisäämällä potilaan soluihin pysyvällä 
tavalla toimiva versio puuttuvasta tai viallisesta geenistä. Geenin lisääminen eli integraatio 
saadaan aikaiseksi käyttämällä vektoreiksi kutsuttuja geenikuljettimia, joilla on kyky liittää 
haluttu DNA-molekyyli kohdesolun kromosomistoon. Esimerkki tällaisesta vektorista on 
ihmisen immuunikatovirukseen (HIV-1) perustuvat vektorit, joilla on monia etuja muihin 
geeninsiirtomenetelmiin verrattuna. HIV-1 muutetaan vektoriksi poistamalla siitä kaikki 
komponentit jotka osallistuvat taudinaiheutukseen ja jotka mahdollistavat viruksen 
lisääntymisen isäntäsolussa. Jäljelle jäänyt partikkeli kykenee vain viemään hoitavan 
geneettisen materiaalin soluun ja liittämään sen osaksi isäntäsolun kromosomistoa. 
Geenien integraatio ei kuitenkaan ole ongelmaton tapahtuma, koska vääriin paikkoihin 
liittyessään hoitogeeni voi haitata solun omien geenien normaalia toimintaa. Pahimmassa 
tapauksessa tämä voi johtaa uusien sairauksien, kuten syövän, syntyyn. Integroituvia 
vektoreita onkin turvallisinta käyttää ns. ex vivo-sovelluksissa, jotka mahdollistavat vain 
oikealla tavalla muokattujen solujen valinnan ja niiden siirtämisen takaisin potilaaseen. 
Tällainen solujen valintaprosessi voi kuitenkin olla työläs toteuttaa, ja kaikkiin nykyisin 
käytössä oleviin vektoreihin liittyy haitallisten mutaatioiden, ja sitä kautta ei-toivottujen 
haittavaikutusten, aiheuttamisen riski. 
Tämän työn tavoite on ollut kehittää turvallisesti integroituva geeninsiirtovektori, 
jollainen geeniterapian vektorivalikoimista toistaiseksi puuttuu. Työssä muokattiin HIV-1-
pohjaisen vektorin integraasi-proteiinia, joka vastaa siirtogeenien liittämisestä isäntäsolujen 
kromosomistoon. Integraasiin liitettiin I-PpoI-proteiini, joka tunnistaa ihmisen genomissa 
alueita ribosomaalisesta DNA:sta.  Siirtogeeni ajateltiin voitavan liittää tälle alueelle ilman 
että solun normaalille toiminalle aiheutuisi siitä haitallisia sivuvaikutuksia. Jotta luodun 
yhdistelmäproteiinin toimintaa voitiin tutkia parhaat sovellusmahdollisuudet omaavassa 
muodossa, kehitettiin menetelmä sen pakkaamiseksi HIV-1 -pohjaisiin vektoreihin. Tämän 
pakkausmenetelmän käytettävyyttä myös muiden geeniterapian saralla mahdollisesti 
hyödyllisten proteiinien solukuljetuksessa tutkittiin luomalla uusia integraasi-
yhdistelmäproteiineja. LM-PCR:ää ja bioinformatiikkaa hyväksi käyttäen todettiin 
integraasi-I-PpoI yhdistelmäproteiinin lisäävän vektorin integroitumista toivotulle 
ribosomaalisen DNA:n alueelle. Tämän lisäksi todettiin kehitetyn 
proteiinikuljetusmenetelmän soveltuvan geenien korjauksessa sekä kohdennetussa 
integraatiossa käytettävien entsyymien soluvientiin. Työssä saavutetut tulokset voivat olla 
laajemminkin hyödynnettävissä tutkimuksissa, jotka tähtäävät erilaisten sairauksien 
hoitamiseen geeniterapialla ilman ei-haluttuja ja hoidon turvallisuutta uhkaavia 
sivuvaikutuksia.  
 
Luokitus: QZ 52, QU 470, QW 168.5.R18, QU 55 
Yleinen suomalainen asiasanasto: geeniterapia; geeninsiirtomenetelmät; geneettiset vektorit; retrovirukset; 
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1 Introduction 
Gene therapy is the treatment of inherited or acquired diseases by temporal or permanent 
introduction of therapeutic nucleic acids into a patient’s cells. It can also involve the 
correction of disease-underlying mutations in a patient’s genes, called genome editing. 
The therapeutic genetic material usually consists of a transcription unit, in which the 
transferred gene is accompanied by its necessary control elements such as promoters and 
enhancers. When these elements become integrated into the target cell’s genome, they can 
alter the activity status of cellular genes, extending their effects to considerable distances. 
If transcriptional deregulation by vector-derived sequences affects host genes that have 
important roles in cellular division and growth, the cells can escape from their normal 
growth restriction and become transduced or cancerous cells. In fact, transgene integration 
through any other mechanism than homologous recombination is inherently associated 
with insertional mutagenesis, which can have genotoxic consequences through different 
mechanisms. The targeting of transgene integration into safe sites within the target cell’s 
genome represents a solution to the safety risks associated with integrating gene transfer 
vectors. Therefore, several methods are being developed to minimize the risks of 
inadvertent cellular gene activation and other forms of genotoxicity.  
The aim of this work was to introduce modifications to vectors derived from Human 
Immunodeficiency Virus 1 (HIV-1) in order to study whether transgene integration could 
be targeted to a genomic safe harbor locus, the ribosomal DNA. In addition, this work 
explores the possibilities of using lentivirus vector particles for protein transduction with a 
previously unexploited approach. The results obtained in this work demonstrate that 
integrase fusion proteins are able to modify vector integration site selection in human 
cells. Moreover, it was devised that vector particles containing the introduced integrase 
fusions proteins are suitable for the cellular delivery of different proteins both in the 
absence or presence of concomitant gene transfer. While the first finding broadens the 
selection of available approaches for targeted gene integration with lentivirus vectors, the 
second can be considered to benefit many types of applications such as gene correction, 
site-specific gene insertion through DNA double strand breaks and temporal 
manipulation of target cell’s signaling cascades. The vector modifications and findings 
presented here may prove useful to many areas of gene therapy, including safer 
permanent gene transfer and vectorization of proteins with a range of therapeutic 
applications.  
 
2 
 
 
2 Review of the literature  
2.1 GENE THERAPY 
2.1.1  Basic concepts of human gene therapy 
Gene therapy is the treatment of acquired or inherited diseases by introducing genetic 
material into the patient’s cells or organs with the aim of curing a disease, alleviating its 
symptoms or slowing down its progression (Verma and Weitzman 2005). The therapeutic 
genetic material, which can be either DNA or RNA, is transferred into the target cells with 
the assistance of gene transfer vehicles called vectors. In ex vivo gene transfer, specific 
cells of the patient are extracted, expanded in culture, treated with appropriate gene 
transfer vectors and finally introduced back into the patient. In vivo gene transfer occurs 
directly into the tissues of the patient. Unfortunately not all cell types can be successfully 
cultured outside of the body and then re-introduced, and therefore many conditions can 
only be treated by in vivo gene therapy of somatic cells.  
2.1.2 Gene transfer vectors 
Gene therapy vectors can be divided into different classes according to their origin (viral 
or non-viral) and on the type of gene transfer they promote (permanent versus transient). 
Viruses have evolved efficient strategies to transport their DNA or RNA genomes into 
cells to harness the host for progeny virus production. With the exception of certain 
vectors used for cancer treatments, viral vectors are engineered by removing the 
sequences essential for virus replication and pathogenicity, and replacing them with the 
desired genetic material to be delivered into the target cells (Kootstra and Verma 2003; 
Verma and Weitzman 2005). Gene transfer with viral vectors, called transduction, is often 
efficient due to the inherent ability of viruses to infect different cell types. The general 
drawbacks of viral vectors include potential elimination of the vectors or transduced cells 
from the organism due to immunological responses elicited against viral proteins. Other 
limiting factors for viral vectors’ use in gene therapy may arise from difficulties in 
producing sufficiently large amounts of pure vectors.   
Non-viral vectors are based on transferring DNA or RNA into cells with the aid of 
physical or chemical means, collectively called transfection (Verma & Weitzman 2005). 
Non-viral vectors can range from a simple plasmid DNA containing one gene of interest 
(GOI) to more complex DNA-based systems capable of transgene integration. Non-viral 
vectors generally suffer from limited in vivo transfection efficiency, but they are easy to 
produce in high quantities and generally they elicit low immunological responses.  
Hybrid vectors are generated by combining the desired features from different viral or 
non-viral vectors. In addition to the GOI, all vectors typically contain auxiliary cis-
elements that control the expression of the transgene and improve vector production and 
functionality.  
Permanent or long-term gene transfer is accomplished by using integrating vectors that 
catalyze the attachment of the GOI into the genome of the target cell (Kootstra & Verma 
2003). When a cell undergoes cellular division, it duplicates its chromosomes to yield two 
daughter cells with identical genomes. Integrated transgenes are duplicated along with the 
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cellular genome and are inherited by the daughter cells. Transgene integration is necessary 
when sustained, even life-long, expression of an introduced gene is desired, for example 
when treating monogenic inherited diseases by gene therapy. The aim is to introduce a 
functional copy of a gene whose absence or malfunctioning is causing the disease. In 
addition to gene augmentation, genome editing represents one form of permanent 
modifications introduced into target cells. In the context of gene therapy, genome editing 
involves introducing predetermined sequence changes to the chromosomal DNA with the 
goal of correcting the mutations that underlie a certain disease (Perez-Pinera et al. 2012). In 
some instances, a therapeutic benefit can also be achieved by disrupting the coding region 
of an endogenous gene, as in the case of restricting viral infection (Holt et al. 2010). 
Non-integrating vectors generally promote transient expression of transgenes (Kootstra 
and Verma 2003). These are present in nuclei as extrachromosomal DNA, which is 
generally not duplicated with the cellular genome. In dividing cells, the non-integrated 
genetic material is therefore eventually lost due to dilution. Non-integrating vectors are 
generally used to treat acquired conditions such as cancer, where short-term expression of 
a therapeutic gene product can elicit the expected therapeutic outcome. However, certain 
non-integrating vectors, such as episomal vectors and artificial chromosomes, can promote 
long-term transgene expression in the absence of integration (Verma and Weitzman 2005). 
They are maintained in the nucleus through specific elements and become replicated 
autonomously or along with the genomic DNA.  
Non-integrating vectors do not necessarily carry an expressed transgene, as they may 
also be harnessed to ferry RNA molecules or proteins into cells. Protein transduction is a 
special approach which can be achieved by using viral vectors or protein moieties for the 
cellular delivery of desired molecules with specific functions (Wagstaff and Jans 2006). In 
addition to the protein of interest, these kinds of vectors may also contain a transferred 
genetic cargo. 
2.1.3 Vectors in clinical gene therapy trials 
Different gene therapy treatments need to be verified as safe and functional in clinical 
gene therapy trials; this involves three to four steps, or phases. Successful completion of 
phase III studies enables applying for a marketing license for the treatment (Gonin et al. 
2005). The first and currently only gene therapy treatment that has received a positive 
opinion on the marketing authorization by the European Medicines Agency (EMA) is 
Glybera, a treatment for the ultra-orphan disease lipoprotein lipase deficiency (European 
Medicines Agency 2012).  
The majority of clinical gene therapy trials are conducted using viral vectors (Figure 1). 
In total, 81.5% of gene therapy clinical trials address three diseases: cancer (64.4%), 
inherited monogenic diseases (8.7%) and cardiovascular disease (8.4%) (Ginn et al. 2013). 
The currently most widely used vectors (Figure 1) are based on adenoviruses, which are 
non-enveloped DNA viruses with a double stranded genome of approximately 36–40 kb 
(Verma and Weitzman 2005). Adenovirus vectors can infect a wide range of organs, are 
easy to produce in large quantities and are resistant to environmental factors. In gene 
therapy, they can be used to treat diseases such as cancer in which transient expression of 
a therapeutic gene in the relevant tissue is sufficient for the therapeutic outcome (Warnock 
et al. 2011). The most developed adenoviral vectors, called ‘gutless vectors’, have been 
deleted of all viral gene products.  The use of adenoviral vectors in gene therapy can be 
challenging due to the recognition of the remaining adenoviral proteins by the innate 
immune system, which can lead to acute toxicity and rapid elimination of adenoviral 
particles after their intravenous delivery. In addition, long-term expression of transgenes 
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after adenovirus vector transduction may be hampered due to the adaptive immune 
responses against viral particles and transgene products (Warnock et al. 2011). 
Retrovirus vectors are the second largest group of vectors being utilized in gene therapy 
trials and they represent the most popular choice for integrating vectors (Ginn et al. 2013). 
Clinical trials conducted with retroviral vectors have focused on treating monogenic life-
threatening conditions mainly affecting the immunological system.  The main types of 
integrating vectors will be described in the following sections of the literature review, with 
a focus on retroviral and lentiviral vectors.  
 
 
Figure 1. Vectors used in gene therapy clinical trials (reproduced after Ginn et al. 2013).    
 
2.2 GENOTOXICITY 
Any physical or chemical agent that causes damage to and compromises the integrity of 
genomic DNA, resulting in mutations or cancer, can be called a genotoxin. Genetic 
damage can occur spontaneously e.g. during DNA replication, or it can be induced by 
mutagens (Lewin 2004). Both endogenous factors and exogenous stress represent sources 
of mutagens, ranging from reactive oxygen species that arise as a byproduct of cellular 
energy metabolism to UV irradiation. DNA damage can be mutagenic, carcinogenic or 
teratogenic; i.e. causing alterations into the genetic code, leading to cancer or causing fetal 
malformation, respectively. Mutations are changes in the DNA sequence that can occur at 
single bases (point mutations) or affect larger genome areas (Lewin 2004). Mutagens such 
as UV irradiation can increase the incidence of point mutations, whereas mutations caused 
by gene transfer vectors are usually due to insertions of one or more base pairs 
(insertional mutagenesis) (Wu & Dunbar 2011). Integrating viral and non-viral vectors 
rely on the activity of specific proteins that are specialized in undertaking distinct 
enzymatic steps necessary for the attachment of one DNA molecule to another DNA 
molecule. Integration may require several steps, e.g. DNA excision, ligation and 
replication, which can in addition to insertional mutagenesis, lead to structural 
chromosome abnormalities such as deletions, insertions, inversions and other 
rearrangements.  
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2.2.1 Different outcomes of transgene integration 
Integrating vectors obligatorily modify the host cell’s genome by introducing new 
sequences into it, thereby potentially acting as genotoxins and insertional mutagens. The 
cellular effects of transgene integration depend on the genomic site at which the 
integration occurs and on the type of sequences being inserted (Hackett et al. 2007; Voigt 
et al. 2008). If a new DNA sequence is inserted into heterochromatin or genomic areas that 
contain no important regulatory or coding sequences, the effect of the insertion on the cell 
can be zero (silent mutation). However, if the inserted DNA lands on protein-coding 
genes or gene regulatory areas, harmful mutations become more likely. Vector integration 
can cause a null mutation if the inserted DNA disrupts a cellular gene and totally 
abolishes its function. Insertion within a coding sequence may result in truncated or non-
functional transcripts, which can have genotoxic consequences (Fig. 2).  
The insertion of vector sequences may also give rise to a new function or change the 
expression pattern of cellular genes. This kind of insertional mutagenesis is called a gain-
of-function mutation (GOF) (Hackett et al. 2007). Transcriptional deregulation of cellular 
genes is mainly induced through the insertion of vector-contained promoter and enhancer 
elements, which can affect the expression levels of sequences as distant as 100-275 kb from 
the insertion site (Maruggi et al. 2009; Papapetrou et al. 2011). Integration of these 
elements close to the transcription start sites and other cellular gene regulatory areas poses 
a particularly high risk of endangering endogenous gene function (Trobridge 2011). Post-
transcriptional deregulation is also possible through the insertion of splicing and 
polyadenylation signals within vector sequences.  These elements together with the 
vector-borne promoters and enhancers may induce aberrant splicing, premature transcript 
termination, and the generation of chimeric viral-host read-through transcripts, that have 
novel and potentially genotoxic activities (Maruggi et al. 2009; Moiani et al. 2012; Montini 
et al. 2009).  
When vector insertion eliminates or reduces the activity of a gene, it causes a loss-of-
function mutation (LOF) (Hackett et al. 2007). LOF-mutations are generally recessive and 
less harmful than GOF mutations that are usually dominant. In the most severe cases, 
GOF-mutations affect cellular genes important for growth control, namely oncogenes or 
tumour suppressor genes, leading to the development of cancer. Therefore, insertional 
mutagenesis can also be oncogenic.  The different consequences of transgene insertion for 
cellular genes are summarized in Figure 2. 
2.2.2 Genomic safe harbors for transgene integration 
Any DNA introduced into cells by vectors can theoretically become integrated into the 
host cell’s genome, but integrating vectors carry a particularly high risk of insertional 
mutagenesis.  Thus, if one wishes to avoid genotoxic outcomes of transgene integration, 
then controlling the site of gene insertion is of the utmost importance. The optimal site for 
transgene integration would be at extragenic genomic locations that could allow 
predictable expression of the introduced gene without adversely affecting the host cell or 
organism through genotoxicity (Sadelain et al. 2011). Five criteria have been proposed for 
a true genomic safe harbor (GSH) for transgene integration: (i) distance of at least 50 kb 
from the 5′ end of any gene, (ii) distance of at least 300 kb from any cancer-related gene, 
(iii) distance of at least 300 kb from any microRNA, (iv) location outside a transcription 
unit and (v) location outside non-coding intragenic or intergenic regions that are 
completely conserved in the human, mouse and rat genomes (ultraconserved regions) 
(Papapetrou et al. 2011). These criteria are based on defining a locus for integration, where 
the integrated DNA would have minimal effects on: (i) the natural expression of cellular 
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genes, (ii) activation of proto-oncogenes or inactivation of tumor suppression genes, (iii) 
affecting important cellular regulatory processes, (iv) inactivating cellular genes and (v) 
affecting areas enriched with enhancers and exons. Although many genomic locations 
have been proposed as GSHs and targeted for integration with different means, successful 
methods to target a strictly defined GSH remain to be devised (Sadelain et al. 2011). 
Figure 2. Possible mutagenic consequences of transgene integration in or close to a cellular 
transcription unit (modified from Nowrouzi et al. 2011). A) A silent mutation, integration into 
e.g. heterochromatin. B and C) Activation of neighboring genes by enhancer elements present 
within the vector (GOF). D and E) Gene deregulation due to strong internal promoters that can 
lead to viral-host gene-fusion transcripts (GOF/LOF). F) Inactivation of cellular genes by vector 
insertion that causes truncated or non-functional transcripts (LOF/null mutation). TSS, 
transcription start site. The black horizontal lines represent expressed and spliced transcripts. 
2.2.3 Resolving vector integration sites 
Characterizing the cellular integration sites of a vector is critical for assessing the risk of 
insertional mutagenesis and understanding and potentially avoiding vector-related 
genotoxicity (Kustikova et al. 2010; Wu and Dunbar 2011). Integration sites (IS) in the 
genomic DNA of transduced cells can be studied using different methods, many of which 
utilize the polymerase chain reaction (PCR). Generally PCR is designed so that 
amplification extends from a known integrated vector sequence towards the unknown 
genomic DNA that contains the integration site information. The junction fragment is 
amplified and sequenced, and the resulting read data is bioinformatically processed and 
analyzed to match unique integration sites in the human genome. The IS sequence data 
obtained from vector integrome studies is analyzed with different methods to assess the 
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vector’s genotoxic potential. IS analysis commonly involves retrieving information relating 
to the chromosomal features around the ISs, the genes potentially affected by the insertion 
and clustering of ISs within regions known to underline cellular transformation events.  
Due to the limitations of the Sanger sequencing technology, next generation sequencing 
methods, such as the 454 and Illumina, have become the methods of choice to resolve 
integration site data from complex samples containing multiple integration sites (Metzker 
2010; Strausberg et al. 2008).  
Many techniques used for identifying integrated proviral (vector genome) and host 
genomic DNA junctions involve cleaving the genomic DNA with restriction enzymes 
(REs) in order to amplify the sequence of interest. Examples include the plasmid rescue 
method (Kurdi-Haidar and Friedmann 1996) and several PCR-based methods such as 
linear amplification-mediated polymerase chain reaction (LAM-PCR, Schmidt et al. 2007; 
Schmidt et al. 2002),  ligation-mediated PCR (LM-PCR, Mueller and Wold 1989) and 
inverse PCR (Jin et al. 2002; Ochman et al. 1988; Silver and Keerikatte 1989). Full recovery 
of cellular ISs with techniques that depend on REs is impossible, because some of the ISs 
will evade detection due to their occurrence being too close or too far from a RE site. If a 
RE site resides in the close proximity of an integrated vector sequence, the resulting 
fragment can be too small to be resolved. Alternatively, fragments too long to be amplified 
can be produced if the RE site resides distant from the integrated vector. Due to the 
uneven occurrence of RE-sites in the genome, RE-dependent methods produce IS 
information with an inherent restriction site bias (Wang et al. 2008; Gabriel et al. 2009). The 
bias can, however, be bioinformatically accounted for in the data analysis step by 
generating so-called matched random control sites (MRCs) that contain the same potential 
bias (Berry et al. 2006; Mitchell et al. 2004). In addition, new RE-independent methods 
have been developed to improve the unbiased resolution of ISs, and to be able to 
accurately quantify the relative contributions of individual integration site containing 
clones in a polyclonal setting. These include a MuA transposase based method (Brady et 
al. 2011), non-restrictive LM-PCR (Gabriel et al. 2009; Paruzynski et al. 2010; Wu et al. 
2013) and flanking-sequence exponential anchored PCR (FLEA-PCR, Pule et al. 2008). 
Despite the advances in  method sensitivity and improved IS coverage, the current 
extraction methods still seem to be challenged by bias-related issues, since access to the 
full integrome may be restricted by secondary structure motifs of the flanking DNA, or 
other factors not related to the primary DNA sequence (Wu et al. 2013).  
 
2.3 RETROVIRUSES AND RETROVIRAL VECTORS 
Retroviruses are a large and diverse family of enveloped RNA viruses that have a unique 
life cycle among all viruses as they replicate via a double stranded DNA intermediate 
(Goff 2007). Their genome consists of two copies of a linear single stranded RNA molecule 
of 7-12 kb, which are protected by a protein core inside the enveloped virus particle. 
According to the complexity of the viral genomes, retroviruses can be categorized into so- 
called simple and complex retroviruses. The first class includes the genera of alpha-, beta- 
and gammaretroviruses, and the latter group contains the delta- and epsilon-retroviruses, 
lentiviruses and spumaviruses. Three open reading frames (ORFs) are common to all 
retroviruses: gag (group associated antigen) encoding for structural proteins, pol encoding 
for the proteins needed in viral replication, and env encoding for the envelope 
glycoproteins that mediate virus entry.  In contrast to simple retroviruses that contain no 
other reading frames, complex retroviruses also express several small regulatory proteins 
8 
 
 
with a range of functions (Goff 2007). All retroviral genomes are flanked by two long 
terminal repeat (LTR) sequences and contain cis-acting packaging sequences (phi, Ψ) that 
is needed for the correct incorporation of unspliced genomic RNA molecules into new 
virus particles (Figure 3). 
 
Figure 3. The proviral genome organization of a simple retrovirus (MLV, top) and a complex 
lentivirus (bottom, HIV-1). Essential cis-acting features are depicted in red; green boxes mark 
the genes of structural and enzymatic proteins and auxiliary genes are marked in cyan (except 
for rev in the HIV-1 genome). U3 and U5, unique sequences to the 3’ and 5’ LTRs, 
respectively; R, repeated sequence. Viral gene products and abbreviations are explained in the 
text. (Figure reproduced after Verma and Weitzman 2005).  
 
In gene therapy, the term (simple) retrovirus usually refers to vectors derived from 
gammaretroviruses (γRV). Historically most widely used γRV vector (γRVV) in gene 
therapy trials is based on (Moloney) murine leukemia virus (MLV). The second largest 
genus of retroviruses that have been exploited as tools for gene transfer is the lentiviruses 
(LVs). Lentivirus vectors (LVVs) used in clinical trials are typically derived from human 
immunodeficiency virus 1 (HIV-1). Together γRVVs and LVVs comprise 22.6% of all the 
vectors used in gene therapy trials (Ginn et al. 2013). 
Other members of the retrovirus family that have recently attracted interest as gene 
therapy vector platforms are the alpharetroviruses and spumaviruses.  Spumaviruses  are 
complex retroviruses that are apathogenic in humans, and the several unique features they 
possess compared to γRVVs or LVVs make them attractive candidates for gene therapy 
(Linial, 1999).  Alpharetroviruses have been suggested to be safer gene transfer vehicles 
than γRVVs or LVVs due to their different integration pattern (Suerth et al. 2012). The 
following sections will focus on describing the two most used gene therapy vectors based 
on retroviruses, the MLV-derived γRVVs and the HIV-1 -derived LVVs. 
2.3.1 Retrovirus life cycle   
The retroviral life cycle is divided into two phases, early and late. The early phase 
encompasses virus entry, reverse transcription and integration; thus transportation of the 
viral genome into the target cell and its subsequent integration into host DNA. The late 
phase involves expression of the virus genome and the production of progeny viruses. 
With the exception of spumaviruses, the most important features of the retrovirus life 
cycle are shared between the different genera of retroviruses (Goff 2007).  
The early phase of the retroviral life cycle begins by binding of the virus to the cellular 
membrane (Fig. 4A). Interaction of the envelope glycoproteins with receptors on the 
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cellular surface leads to virus internalization through membrane fusion or endocytosis 
(Nisole and Saïb 2004).  After gaining entry into the host cell, the virus becomes uncoated 
and the RNA genome is reverse transcribed into double stranded DNA by the viral 
enzyme reverse transcriptase (RT) (Figure 4).  The processing of the RNA genome into a 
complementary DNA (cDNA) molecule takes place within a large complex called the 
reverse transcription complex (RTC) that includes at least the viral proteins nucleocapsid 
(NC), RT, integrase (IN), and the viral RNA. After completion of reverse transcription, the 
protein-cDNA complex, now designated the preintegration complex (PIC), traverses the 
cytoplasm towards the nucleus. In addition to viral proteins, PICs contain several cellular 
proteins which may aid in nuclear translocation and can act as cofactors for correct 
integration (Raghavendra et al. 2010).  The large size of the PIC precludes nuclear entry by 
passive diffusion, and retroviruses have evolved different strategies to gain access to the 
genomic DNA for integration to occur. Lentiviral PICs become internalized into the 
nucleus of both dividing and non-dividing cells through active transport (Bukrinsky et al. 
1992; Lewis et al. 1992), but simple retroviruses depend on the break-down of the nuclear 
envelope during mitosis to become internalized (Roe et al. 1993). Once inside the nucleus, 
the PIC-associated viral IN protein catalyzes attachment of the viral cDNA into the 
genomic DNA.   
 
Figure 4. The life cycle of a retrovirus and structure of a mature HIV-1 virion. A) The life cycle 
of a retrovirus begins by binding of the virus to receptors on the plasma membrane of the 
target cell, followed by its internalization into cytoplasm. The RNA genome is reverse 
transcribed in the RTC, after which it is transported to the nucleus within the PIC. IN catalyzes 
cDNA integration into the cellular genome. Provirus transcription yields genomic RNA and RNA 
molecules which are translated to viral proteins and precursor polyproteins.                
B) Structure of a mature HIV-1 virion (modified from: 
http://idshowcase.lshtm.ac.uk/id501/ID501/S1S2/ID501_S1S2_050_010.html.) Pbs, primer 
binding site; ppt, polypurine tract; pA, polyadenylation signal. Abbreviations for the viral genes 
and gene products are explained in the text.  
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The late phase of the retrovirus life cycle begins when the integrated virus genome, the 
provirus, is expressed by the cellular polymerases to yield proteins and genomic RNA 
molecules necessary to construct progeny virus particles (Goff 2007). Provirus expression 
initiates from the enhancer and promoter sequences residing in the U3 region of the 5’LTR. 
A fraction of the RNA molecules produced become spliced and translated into viral 
proteins. Another fraction becomes exported from the nucleus as single-spliced or non-
spliced genomic RNA molecules. New virus particles start to form at the plasma 
membrane initiated by the assembly of expressed Gag (Pr55Gag) and GagPol 
(Pr160GagPol) precursor polyproteins, Env proteins and two copies of viral genomic RNA. 
The packaging and dimerization signal Ψ of the virus genomic RNA guides its 
incorporation into newly forming virions. The Env-glycoproteins are incorporated into the 
viral membrane during the budding process. The newly formed virion matures through 
protease (PR)-catalyzed cleavage of Gag and Gag-Pol precursors. Gag processing gives 
rise to the structural proteins matrix (MA, p17), capsid (CA, p24) and NC (p7), p6 and two 
small spacer peptides (p1 and p2).  The Env is processed to yield the surface (SU, gp120) 
and the transmembrane (TM, gp41) proteins and Pol is processed to protease (PR), RT and 
IN (Goff 2007).  The structure of a mature HIV-1 particle is depicted in Figure 4 B.  
2.3.2 Integration 
For all members of the retrovirus family, the LTR-flanked viral genome is integrated into 
the host chromatin in a similar three step process catalyzed by the viral IN. In the first step 
called 3’ end processing, IN releases a di- or trinucleotide from the 3’ ends of the blunt-
ended LTRs to expose a 3’ hydroxyl (OH-) group attached to the invariant CA 
dinucleotide (Goff 2007). An OH-group of water provides the source of the initial 
nucleophile attack. IN next catalyses the strand transfer step, where the target DNA is 
cleaved and a new phosphodiester bond between the viral DNA and the target DNA is 
formed in a one-step transesterification reaction. The 3’OH group of the recessed LTR 
provides the source for the second nucleophile attack, and the 3’ ends of the viral DNA 
molecule are inserted into opposing strands of host cell chromosomal DNA. The last step 
of integration, called 5’ end ligation, involves the activity of cellular DNA repair proteins 
that finalize the integration process by cleaving off the mismatched nucleotides of the 
unpaired 5’ ends of the viral LTRs, and covalently join the unattached DNA strands 
(Skalka & Katz 2005; Smith et al. 2008). As a result, the cleaved host DNA sequence is 
repeated at both ends of the integrated provirus, with its length depending on the 
retroviral species.   
2.3.2.1 Structure of the integrase protein and organization of the intasome 
INs of the different genera of the Retroviridae share a similar domain organization that 
includes an N-terminal domain (NTD) with a zinc finger motif, a central catalytic core 
domain (CCD), and a less conserved C-terminal domain (CTD) (Figure 5 A)(Goff 2007). 
Some retroviruses contain an additional NTD extension domain (NED) (Hare et al. 2010). 
The conserved His and Cys residues in the NTD bind a single Zn2+ ion which stabilizes its 
three-helical structure. The CCD contains an D,D-X35-E catalytic triad (Asp-Asp-Glu)-
motif that is conserved from retroviruses to certain bacterial transposase proteins. The 
positively-charged CTD possesses sequence non-specific DNA binding activity (Engelman 
et al. 1994). Assigning specific function to the CTDs has been difficult, but it has been 
postulated to play a role in generating protein contacts that ultimately protect HIV-1 IN 
from proteasomal degradation (Zheng et al. 2011) and participate in the nuclear import of 
lentiviral PICs (Larue et al. 2012). 
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The functional IN complex, or the intasome, consists of two IN dimers, the inner and 
the outer dimer (Hare et al. 2010). The inner subunits elicit the most important IN-
functions, as they bind the viral DNA, are responsible for catalysis and make all contacts 
involved in tetramerization. The outer subunits, for which only the CCDs have been 
resolved, appear to provide structural support. Different IN domains do not have discrete 
functions in the intasome, but all contribute to extensive protein-protein and protein-DNA 
contacts. The roles of the NTDs in the inner dimer are stabilization of the dimer-dimer 
interface through interacting with the CCDs of the opposing inner IN monomer.  In the 
resolved structure, the CTDs localize next to the target DNA-binding cleft (Figure 5 B). 
The molecules within each dimer interact through an extensive CCD-CCD interface (Hare 
et al. 2010). Although γRVV and LVVs integrate through a similar mechanism, they have 
different integration preferences in the cellular genome, which affects their use as gene 
therapy vectors. 
 
Figure 5. Structure of the HIV-1 integrase and organization of the intasome (modified from 
Poeschla 2008 and Hare et al. 2010). A) The figure shows the different domains of the HIV-1 
IN, and the amino acids in the CCD that are crucial for IN activity. The locations and identifiers 
of the amino acids that contact HIV-1 IN’s most important cellular cofactor, the lens 
epithelium-derived growth factor p75, are shown below the schematic. B) The structure of a 
retroviral intasome.  The domains belonging to the two inner subunits (inner-1 and inner-2) 
are shown. Only the CCDs of the outer subunits are shown. The viral LTR sequences (“viral 
DNA”) flank the cleft in the center of the structure, to which target DNA is thought to localize.  
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2.3.2.2 Different retroviruses have distinct integration preferences 
The different genera of retroviruses integrate into the cellular chromatin with different 
characteristics (Bushman et al. 2005; Ciuffi and Bushman 2006). Integration into the 
genome is not random, and each genus has a weak, symmetric integration site sequence 
consensus (Wu et al. 2005). There are also genus-specific biases in the distribution of ISs 
within the cellular DNA with regard to many genomic features, such as transcription 
units, CpG islands and epigenetic marks (Bushman et al. 2005). To date, the integration 
patterns of LVs and γRVs have been thoroughly characterized, and more information 
begins to be available also concerning the other retroviral genera.  
The dinucleotide CpG is underrepresented in the human genome because methyl-GpG 
dinucleotides are readily mutated to TpG dinucleotides. Undermethylated CpG 
dinucleotides can, however, be found clustered in so called CpG islands, which are 
enriched in and around gene promoters (Lewin 2004). A high CpG island frequency at 
large genomic windows indicates an area enriched with genes and gene regulatory areas 
(Lander et al. 2001). CpG islands can therefore be used as markers of promoters at small 
genomic windows, and of gene dense regions when larger windows are considered.  
The content of the nucleotides G and C varies in the genome, with clearly identifiable 
regions that have much higher or lower GC-percentages than the genome-wide average of 
41% (Lander et al. 2001). GC-rich regions are generally gene-rich and have short introns 
and high frequencies of CpG islands. A DNase hypersensitive site is a genomic site where 
an unusual organization of nucleosomes, renders the site about 100-fold more sensitive for 
digestion with DNase I and other nucleases, than the surrounding DNA (Lewin 2004). 
These surrogate markers for accessible chromatin are generally associated with gene 
regulatory regions, CpG islands, highly conserved sequences and transcription factor 
binding sites (Crawford et al. 2006). 
The prototype γRV MLV favors integration near transcription start sites (TSS), DNase -
hypersensitive sites, and into other features associated with promoters and TSSs of active 
genes, such as certain histone methylation marks and areas rich in CpG density and GC 
content  (Cattoglio et al. 2010; Mitchell et al. 2004; Roth et al. 2011; Schröder et al. 2002; Wu 
et al. 2003). Gene-rich regions and active transcription units are also favored for 
integration by LVs, but they tend to integrate throughout the body of genes, away from 
gene regulatory regions (Wang et al. 2007; Berry et al. 2006). In addition, the positive 
correlation of HIV ISs with a high content of DNase hypersensitive site only at longer 
intervals supports this view.   
Both γRVs and LVs favor integration in regions of high GC content, when looking at 
large window sizes around the IS, which is in accordance with the viruses’ preference 
towards promoters and gene-rich areas, respectively. At smaller window sizes (<2kb), 
however, LVs show a preference for AT-rich DNA whereas γRVs favor GC-rich regions at 
all window sizes (Wang et al. 2007; Berry et al. 2006). Factors that affect local integration 
preference and influence integration site selection are thought to explain the difference 
(see later). 
Alpharetroviruses and deltaretroviruses display only a weak integration preference 
towards transcription units and CpG islands (Mitchell et al. 2004; Derse et al. 2007). In 
contrast to all other genera studied, betaretroviruses show no integration site preferences, 
displaying a random distribution of integration sites in the host genome (Faschinger et al. 
2008). Unlike γRVs and LVs, spumaviruses do not prefer transcribed genes for integration, 
but have a modest preference for integration near TSSs and a significant preference for 
CpG islands (Nowrouzi et al. 2006; Trobridge et al. 2006; Beard et al. 2007b). 
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2.3.2.3 Factors affecting retroviral integration preferences 
There are many potential factors that can contribute to the formation of IS patterns typical 
for different classes of retroviruses.  These factors include differences in the viral IN 
proteins, the mechanism of nuclear entry, chromatin accessibility, and tethering 
mechanisms (Ciuffi and Bushman 2006). The most important factor explaining the 
difference between MLV and HIV-1 integration patterns is the interaction of the viral 
integration machinery with different host factors.  Efficient LV integration has been shown 
to depend on the presence of a ubiquitous chromatin-associated host protein, the Lens 
epithelium-derived growth factor p75 (LEDGF/p75) (Shun et al. 2007; Vandekerckhove et 
al. 2006). LEDGF/p75 has an N-terminal chromatin binding domain and an IN binding 
domain at its C-terminus, which interacts with specific amino acids in IN’s CCD (Figure 5) 
(Engelman and Cherepanov 2008; Poeschla 2008). It functions essentially by tethering IN 
to the chromatin. The NTD of LEDGF/p75 directs binding to active transcription units and 
contains an AT-hook motif, which most likely explains the integration preference of HIV-1 
for AT-rich DNA (Ciuffi et al. 2005; De Rijck et al. 2010). In cells depleted of LEDGF, 
integration occurs less efficiently and into genomic features typically favored by simple 
retroviruses (Shun et al. 2007). HIV-1 IN interacts with various other cellular proteins, 
such as Hepatoma-derived growth factor related protein 2 (HRP-2), but their impact on IS 
selection is either unclear or less important than that of LEDGF/p75’s (Schrijvers et al. 
2012; Studamire and Goff 2008). LEDGF is thus the major determinant of the integration 
pattern typical for LVs (Ciuffi et al. 2005; Shun et al. 2007).  
With regard to the other potential factors affecting LV IS selection, it is known that 
integration site preferences are not host-specific and neither is integration targeting 
dependent on the route of viral entry into cells or the state of cell cycle (Desfarges and 
Ciuffi 2010; Trobridge 2011). The step of nuclear entry may however impact the site of 
integration into the chromatin, as components of the nuclear trafficking and nuclear pore 
machinery have been shown to be required for HIV to achieve its normal pattern of ISs 
(Ocwieja et al. 2011). 
Unlike for LVs, it has not been possible to identify similar tethering factors for γRV IN 
that would predict viral integration. MLV IN interacts with various host proteins, 
including transcription factors, chromatin and RNA binding proteins and proteins with 
miscellaneous functions (Studamire and Goff 2008). In addition to the γRV IN protein, the 
presence of intact LTRs in vectors or virus genomes influences their integration pattern: 
transcription factors binding the LTR enhancer may synergize with the γRV IN protein in 
tethering retroviral PICs to cellular promoters and enhancers enriched with transcription 
factor binding sites (Felice et al. 2009). A correlation has been found between γRV ISs and 
a collection of histone marks and bound proteins associated with active transcription 
units, which may facilitate identification of more specific cellular factors behind the γRV 
integration pattern (Roth et al. 2011).  For retroviruses of other genera, the mechanisms 
that underlie their integration preferences are currently even less well known than for 
γRVs.  
2.3.3 Generation of retroviral and lentiviral vectors 
When a retrovirus is converted to a gene transfer vector, only the early steps of its life 
cycle are harnessed for gene delivery, culminating into transgene integration. The 
generation of replication competent retroviral or lentiviral particles (RCRs or RCLs) is 
highly undesirable, and their possible occurrence is actively avoided (Sinn et al. 2005). 
Production of retroviral vectors imitates the late steps of the virus life cycle with the 
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exception that the viral proteins and vector RNA genome are produced from especially 
designed vector production constructs instead of from the provirus.  
2.3.3.1 The split packaging design 
Vector production plasmids are designed in such a way that intends to reduce the risks of 
inadvertent RCR and RCL production through recombination between vector constructs 
and other retroviral sequences (Sinn et al. 2005). This is accomplished by separating the 
coding regions for structural and enzymatically active proteins (gag and pol-genes), the 
envelope construct and the retroviral genome into separate expression plasmids. In such a 
split-packaging design, structural proteins and the envelope construct are expressed from 
helper-plasmids, whereas the GOI is located within the vector construct containing the cis-
acting sequences required for vector packaging, reverse transcription and integration 
(LTRs and ψ; RRE additionally for LVVs; Fig. 6). The γRVV packaging system is the most 
advanced split-packaging design because it contains no overlapping regions between the 
coding sequences of Gag, Pol or accessory genes (Hildinger et al. 1999). These vectors can 
be produced by the transient transfection of production plasmids into producer cells, or by 
generating genetically engineered stable packaging cell lines (reviewed in Maetzig et al. 
2011).  
The split-packaging system used to produce the most advanced, so-called third 
generation HIV-1 derived lentivirus vectors is composed of four separate plasmids (Fig. 6): 
(i) a packaging construct containing gag and pol genes; (ii) an env, or pseudotyping 
plasmid encoding for a heterologous envelope protein; (iii) a transgene plasmid (vector 
transfer construct) driven by a heterologous strong promoter; and (iv) a plasmid 
expressing Rev (Dull et al. 1998). The LVV split packaging design is, however, incomplete 
because the packaging signal ψ overlaps with coding sequences derived from gag, env and 
pol (Schambach et al. 2013). All HIV-1’s accessory proteins dispensable for vector 
production have been deleted to increase vector safety, but in contrast to γRVVs, efficient 
LVV production requires the presence of one viral accessory protein, Rev (Dull et al. 1998). 
Rev enhances the nuclear export of singly spliced and unspliced RNA molecules by 
binding to Rev responsive elements (RRE) present on mRNA molecules (Malim et al. 
1989).  Although this kind of sequence similarity may lead to homologous recombination 
between the packaging constructs and the vector, the formation of RCLs by recombination 
events has not been observed to date for the split packaging LVVs (McGarrity et al. 2013; 
Escarpe et al. 2003; Sastry et al. 2003). New techniques, such as Cre/loxP-mediated excision 
of the packaging signal from vector sequences after integration, have been created and can 
be used to further decrease the risks of RCL formation (Luche et al. 2012). LVVs are 
generally produced through transient co-transfection of the production plasmids into 
appropriate producer cells, such as 293T cells (Follenzi & Naldini 2002). The culture 
medium containing the vector is harvested two to three days after transfection, purified 
and concentrated via filtering and ultracentrifugation.   
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Figure 6. The proviral genome organization of HIV-1 (top) and the split-packaging design for 
3rd generation LVV production. Packaging plasmids provide the structural proteins and 
enzymes needed for vector production and gene transfer. VSV-G is a heterologous envelope 
protein used to pseudotype the vector. HIV-1 Rev is needed for the expression of gag and pol 
genes and the accumulation of packageable vector transcripts (Malim et al. 1989). The transfer 
construct forms the vector genome and contains the transgene. CMV, cytomegalovirus 
immediate early promoter; RSV, rous sarcoma virus promoter; pA, polyadenylation signal; 
cPPT, central polypurine tract; hPGK, human phosphoglycerate kinase promoter; GFP, green 
fluorescent protein; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element.   
2.3.3.2 SIN LTRs 
Integration of γRV LTRs into the genome can activate nearby cellular genes at distance of 
up to 100 kb owing to the strong enhancer activity present in the U3 regions of the LTRs 
(Maruggi et al. 2009). In order to minimize LTR-derived transcriptional interference, a self- 
inactivating mutation (SIN) has been successfully introduced into both LVV and γRVV 
transfer constructs (Zufferey et al. 1998; Schambach et al. 2006). When the vector construct 
is transcribed into RNA, the 5’ LTR lacks the U3 region (Figure 4 A). During reverse 
transcription, U3 from the 3’LTR is copied into the 5’ LTR (Goff 2007). Since the SIN 3’LTR 
carries a deletion in the U3 region (ΔU3), the reverse-transcribed cDNA copy of the vector 
RNA genome contains a U3 deletion at both of its LTRs, which minimizes unwanted LTR-
driven expression. In addition, sequences such as polyA enhancers and insulators can be 
incorporated into the 3’ LTR’s ΔU3 region to minimize the possibility for transcriptional 
read-through and to further isolate the inserted construct from its genomic environment 
(Schambach et al. 2013). 
2.3.3.3 Pseudotyping and titering 
The tropism of viral vectors can be altered and improved by replacing their natural 
envelope glycoproteins with heterologous proteins that similarly enable an interaction 
with cell surface receptors and allow cell entry. The G-(glyco)protein of Vesicular 
Stomatitis Virus (VSV-G), is often used to pseudotype LVVs, because it improves the 
stability, titers and target cell tropism of the vectors (reviewed in Cronin et al. 2005). 
However, VSV-G is fusogenic in nature and evokes cytotoxicity at high concentrations 
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(Burns et al. 1993).  Although this poses challenges, it is possible to generate stable 
packaging cell lines for VSV-G pseudotyped LVV production with different methods and 
even for clinical use (reviewed in Sakuma et al. 2012). 
The amount of physical and functional vector particles in a certain volume is assessed 
by vector titering. Physical particle concentrations can be quantified by measuring the 
amounts of particle components in vector preparations, such as the p24 CA concentration, 
RNA-content, RT activity and genome copy numbers (Sastry et al. 2002; Geraerts et al. 
2006). However, physical particle quantification can suffer from limited accuracy owing to 
the presence of empty particles in vector preparations. In particular, the p24-based 
determinations are affected by particle-un-associated p24 and Gag-precursors present in 
producer cell media.   
Functional titers, which indicate the amount of transducing (infectious) particles per 
unit volume, can be assessed by measuring transgene expression in target cells, for 
example by flow cytometry, antibiotic selection or immunostaining methods (Sakuma et 
al. 2012). The measurement of proviral vector DNA copy numbers in infected cells 
provides another means to determine functional titers. This has the advantage of being 
applicable also for the titering of vectors whose transgene expression is difficult to assay. 
Determination of the provirus copy number is superior to the expression-based titering 
methods also because it is less likely to be influenced by factors that can can impact on 
titer determination, such as defective interfering particles and variable vector expression 
levels in different cells (Gay et al. 2012; Sastry et al. 2002).  
2.3.4 Genotoxicity of retroviral gene transfer in clinical gene therapy trials 
The utility of γRVVs has been demonstrated especially in the clinical trials for primary 
immunodeficiencies, which are the second most targeted group of inherited diseases by 
gene therapy (Ginn et al. 2013). The X-linked severe combined immunodeficiency (SCID-
X1) is a lethal condition that results from different mutation in the interleukin-2 receptor 
subunit gamma (IL2RG) gene that encodes for the cytokine receptor common gamma (γC) 
chain of interleukin receptors (Noguchi et al. 1993; Sugamura et al. 1996; Leonard 1996). 
Gene therapy of SCID-X1 involves the integration a functional copy of the γC gene into 
autologous bone marrow cells of the patient, and the reinfusion of these manipulated cells 
into the patients (Fischer et al. 2010). The ex vivo introduction of the γC gene has been 
historically carried out using γRVVs (Table 1).  The immunodeficiency has been corrected 
in 17 out of the total 20 treated patients, but severe adverse events appeared in some of the 
patients 2-6 years after the gene therapy treatment. A clonal T-cell proliferation occurred 
in a total of five treated patients, leading to a leukemia-like disease (acute T-cell leukemia, 
T-ALL) (Hacein-Bey-Abina et al. 2008; Howe et al. 2008). The onset of the aberrant T-cell 
proliferation resulted from the integration preference and the components of the MLV 
vectors used: the therapeutic gene had integrated close to the cellular LMO2 proto-
oncogene, causing its transcriptional activation through enhancer element insertion from 
the vector LTRs. A clonal imbalance of the transferred T-cells resulted in malignant 
consequences. However, not all clinical gene therapy trials conducted with γRVVs have 
resulted in adverse effects (Table 1), and the development of the severe adverse effects 
(SAEs) following γRVV gene transfer is highly context-dependent (Riviere et a. 2012).   
Integration of γRVVs is more genotoxic than that that of LVVs, and the underlying 
reasons for this are the differences in the typical integration patterns of the two viruses 
and in vector design. Because of the γRV integration preference into gene regulatory areas 
(Mitchell et al. 2004; Wu et al. 2003), vector-contained enhancer sequences, most notably 
those from the non-inactivated LTR sequences, have a high likelihood of activating nearby 
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cellular genes. LVVs, in contrast, were early modified to contain SIN-LTRs devoid of 
enhancer elements (Zufferey et al. 1998). This feature associated with the more random 
integration pattern of LVVs within transcription units (Wang et al. 2007) likely explains 
their reduced genotoxicity. The use of LVVs in clinical gene therapy trials has increased 
over the past years, and currently they are being used in a total of 55 trials (Ginn et al. 
2013). The data available to date from clinical trials conducted with LVVs feature one 
clonal dominance event similar to those that led to the onset of T-ALL in the X-SCID 
patients (Cartier et al. 2009; Cavazzana-Calvo et al. 2010). However, this clonal event has 
not been reported to have led to a malignancy. LVs integrate more often close to cancer-
related genes than would be expected through chance (Beard et al. 2007a; Brady et al. 
2009), so any vector-contained enhancer or promoter elements elevate their potential to 
cause cellular transformation. LVV integration in the human genome has been shown to 
induce alternative splicing and generation of aberrant transcripts (Moiani et al. 2012), this 
representing another source for genotoxicity. Probably due to the use of SIN-LTRs in 
LVVs, aberrant activation of cellular genes has not been observed.  
 
2.3.5 Reducing integration-related safety risks 
The two main approaches to decrease the genotoxic potential of integrating vectors are 
targeting integration into GSHs and improving the safety of vector constructs (Trobridge 
2011; Wu & Dunbar 2011) The latter mainly involves deleting sequences with undesired 
cis-activities, such as enhancers and splice signals, and adding elements that improve the 
stability and safety of inserted sequences, such as insulators (Schambach et al. 2013). In 
addition, avoiding multiple copy vector insertions and avoiding the transduction of cells 
with sustained replicative potential are important considerations, as well as a benign 
integration pattern (Kustikova et al. 2010). Moreover, vectors can be made integration 
deficient to reduce the risks of insertional mutagenesis. Such integration defective LVVs 
(IDLVs) or γRVVs can be used to achieve transient transgene expression in dividing cells, 
or long-term expression in non-dividing cells (Wanisch & Yáñez-Muñoz 2009).  
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2.3.5.1 Integration targeting 
Changing the natural integration preference of retroviruses has been mainly pursued with HIV-
1 and LVVs. In order to improve the safety of LVV integration, two main strategies have been 
employed: (i) integrase fusion proteins and (ii) affecting the chromatin binding preference of 
LEDGF/p75, the cellular co-factor of IN. As described before, the HIV-1 IN is composed of three 
domains, the one responsible for generating contacts with the LEDGF/p75 is the CCD (Figure 5).  
Before the IN-LEDGF interaction had been described, directing HIV-1 integration to 
predetermined sites was pursued by generating N-or C-terminal integrase fusion proteins that 
can recognize specific DNA sequences. In the first such study, the DNA-binding domain of the 
phage λ repressor was fused to HIV-1 IN (Bushman 1994). The purified recombinant protein 
showed preferential integration near to the λ-repressor-binding sites present on plasmids. 
Similar in vitro integration targeting results have been obtained by fusing IN with the DNA 
binding domain of the zinc finger protein zif268 (Bushman and Miller 1997), the DNA binding 
domain of the E. coli LexA protein (Goulaouic and Chow 1996; Katz et al. 1996) and with the 
synthetic zinc finger protein E2C (Tan et al. 2004). Translating the IN-fusion protein targeting 
strategy to vectors and cells has not been simple as only one study has reported targeted 
integration with a vector-incorporated IN fusion protein in the cellular context (Tan et al. 2006). 
However, in this study the number of resolved ISs was low and only a slight increase in 
integration near to the intended site was observed (0.99% or 1.48% in comparison to 0.15% by 
the control vector). 
Similar to the IN-fusion protein strategy, retargeting of integration through modifying the 
DNA-binding preference of LEDGF/p75 is based on generating chimeric proteins. LEDGF/p75 
has an N-terminal chromatin binding domain, which can be switched to that of other DNA 
binding proteins. Through transient expression of such chimeras, increased integration within 
heterochromatin and decreased integration within active genes has been achieved (Gijsbers et 
al. 2010; Meehan et al. 2009; Silvers et al. 2010; Ferris et al. 2010). The frequency of vector 
integration into genes was reduced from the 67-72% of the control vectors to 33-60% observed 
with the LEDGF-fusions. Changing the integration preference with LEDGF-chimeras has thus 
resulted in a partial but significant change in the integration preference of LVVs. However, the 
fact that LEDGF/p75 is endogenously present in all human cells complicates the use of this 
approach. LEDGF/p75 chimeras nevertheless represent a proof-of-principle of another means 
for changing the inherent integration preference of LVVs. Affecting the IS selection of other 
retroviral vectors with this strategy is more complicated because their cellular co-factors for 
integration, which likely explains some of the typical integration preference, have remained 
elusive.  
2.3.5.2 Non-integrating lentiviral vectors 
Mutating any of the IN’s essential conserved amino acids in the CCD triad motif (D64, D116 
and E152 in HIV-1) results in impaired provirus formation without affecting other important 
steps in the viral life cycle, such as reverse transcription or the accumulation of viral DNA in the 
nuclei of transduced cells (Engelman & Craigie 1992; Leavitt et al. 1996). A subset of lentiviral 
genomes delivered into target cells becomes circularized as a result of LTR processing through 
non-homologus end joining, homologous recombination or as a byproduct of incomplete 
reverse transcription (Banasik and McCray 2010; Wanisch and Yáñez-Muñoz 2009 and 
references therein). These episomal genomes that contain either one or two LTR sequences (1-
LTR or 2 LTR circles, respectively) are unsuitable as integration substrates but can promote 
episomal expression of vector-contained transgenes. In actively dividing cells, the unintegrated 
episomal DNA is diluted and only transient expression can be obtained. However, in non-
cycling cells transgene expression can last for extended periods of time. The most persistent 
IDLV-driven transgene expression has been obtained in murine retinal pigment epithelium, 
where GFP expression was demonstrated for up to 9 months (Yáñez-Muñoz et al. 2006). IDLVs 
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were also shown to produce a substantial functional rescue in a clinically relevant disease 
model, which can be translatable into targeting IDLV-gene therapy treatment to other 
essentially postmitotic tissues such as muscle, liver and brain. Positive results of IDLV-derived 
expression have been obtained also in the spinal cord (Peluffo et al. 2012) and in human 
vascular smooth muscle cells with a reduced genotoxicity risk when compared to normal LVVs 
(Chick et al. 2012).   
Although negligible amounts of IDLV integration were observed in the study of Yáñez-
Muñoz et al. (2006), low levels of primarily non-IN-catalyzed integration events can occur after 
IDLV transduction (Gaur and Leavitt 1998). The possibility of this kind of illegitimate 
integration is increased after DNA damage, such as DNA double strand breaks, and it is likely 
to be mediated by the non-homologous DNA repair pathway (Ebina et al. 2012). 
2.3.6 Retroviral protein transduction 
In several situations it can be advantageous to deliver proteins of interest into target cells 
instead of expressing them from a vector-delivered transgene. Examples of therapeutic protein 
transduction applications include suicide/prodrug systems such as the Herpes Simplex Virus 
thymidine kinase - ganciclovir treatment (HSV-TK – GCV), formation and modification of 
induced pluripotent stem cells (iPSCs), delivering proteins for the prophylactic immunization of 
patients and transduction of monoclonal antibodies to treat several disorders (Ford et al. 2001; 
Wagstaff and Jans 2006).  
The transportation of proteins or other macromolecules from an extracellular space through 
the plasma membrane can be achieved by fusing them with proteins, peptides or protein 
domains that become taken up by cells when added exogenously. There are several membrane 
and cell penetrating proteins, peptides and protein domains, e.g. the Drosophila homeodomain 
Antennapedia, the HIV-1 Tat protein and the HSV VP22 (Wagstaff and Jans 2006). A completely 
different approach can be adopted by harnessing viral vectors for the cellular delivery of 
desired proteins.  This technology combines the best features of biopharmaceutical 
manufacturing, such as ease of protein production, with the efficient transduction capability 
and predictable pharmacokinetics of viral vectors. 
Different proteins of both γRVs and LVs have been utilized as fusion partners for 
heterologous proteins, leading to their inclusion into virus or vector particles. Both virus types 
are also amenable for the generation of genome-free virus like particles (VLPs), also called 
protein-transducing nanoparticles (PTNs). The HIV-1 accessory protein Vpr has a long history 
of being used as a protein-tether for a variety of viral and heterologous proteins. It is not 
expressed as a part of the gag or gag-pol genes, but becomes packaged into virus and vector 
particles by a protein interaction occurring with the p6 region of Gag (Lu et al. 1993; Paxton et 
al. 1993).  This interaction allows also trans-expressed Vpr and proteins fused to it to be 
incorporated into newly forming virus and vector particles (Wu et al. 1995). The proteins which 
have been incorporated into LVVs and VLPs with the Vpr trans-packaging method include 
antiretroviral agents, nucleases, marker proteins, cytotoxic proteins, and IN-fusion proteins 
(Izmiryan et al. 2011; Joo and Wang 2008; Link et al. 2006; Muthumani et al. 2000; Okui et al. 
2000; Tan et al. 2006; Yao et al. 1999). The method suffers, however, from an important 
limitation: cytotoxic or proapoptotic Vpr-fusion proteins can induce producer cell death, which 
leads to inefficient PTN recovery (Link et al. 2006). Trans-expressed Vpr is incorporated at high 
amounts into LV virions (Singh et al. 2001). Its roles in the life cycle of HIV-1 include cell cycle 
arrest and induction of apoptosis, the latter occurring possibly also in bystander cells (reviewed 
in Zhao et al. 2011). In addition to HIV-1 infected cells, apoptosis is also observed in cultured 
cells after transduction with VLPs that contain trans-packaged Vpr (Maudet et al. 2011). The 
trans-packaging strategy is therefore not an amenable approach for all kinds of applications 
involving different packaged proteins and target cells. 
Other viral proteins that have been used to convert vectors into PTNs include γRV Gag- and 
IN-proteins (Voelkel et al. 2010), HIV-1 Nef (Muratori et al. 2006) and avian sarcoma leukosis 
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virus Gag (Kaczmarczyk et al. 2011). Retroviral protein transduction has several advantages 
over cell penetrating peptides or proteins, e.g. the possibility of pseudotyping the vectors with 
cell-specific antigens to decrease unwanted vector dissemination in vivo, and improved cellular 
entry pathways which are superior to the trafficking of simple protein complexes after 
traversing the cellular membrane (Dalba et al. 2007). 
 
2.4 OTHER INTEGRATING VECTORS  
2.4.1 Adeno-associated viruses 
Adeno-associated viruses (AAVs) are small non-enveloped viruses that belong to the genus 
Erythrovirus of the Parvoviridae (Berns and Parrish 2007). The AAV genome is a linear single-
stranded DNA molecule of about 5kb which contains genes for nonstructural proteins and 
capsid proteins, and is flanked by inverted terminal repeats (ITRs) required for DNA 
replication. The many serotypes of AAVs are non-pathogenic to humans, and can transduce 
several different cell types. Productive AAV infection is dependent on the presence of a helper 
virus, generally an adenovirus or a HSV. In the absence of co-infection, AAVs can establish a 
latent infection that allows genome persistence in infected cells until the required helper 
functions are available.  
Latent infection is established through virus integration into the host genome. For the best 
characterized AAV serotype 2 (AAV2), integration was thought to occur at a specific site on 
human chromosome 19 (19q13.4), also called the AAVS1-site. This site-specific integration 
requires the activity of viral Rep proteins (Rep78/68) and the presence of specific Rep binding 
sites (RBS) on both target DNA and the virus genome (Berns and Parrish 2007). A genome-wide 
study of AAV2 ISs however revealed that integration was scattered over the entire human 
genome, with one third of the sites clustered at three different hotspots located on 
chromosomes 19(AAVS1), 5 (p13.3; AAVS2) and 3 (p24.3; AAVS3) containing consensus RBSs 
(Hüser et al. 2010). Thus Rep activity seems to be a weaker determinant for AAV integration site 
selection than previously thought, and RBS homologues are readily found at numerous 
chromosomal loci. AAV genomes can also persist in cells as extrachromosomal elements for 
extended periods of time (Berns and Parrish 2007).   
2.4.1.1 AAV vector integration 
Vectors derived from AAVs (recombinant AAV or rAAV) have a packaging capacity of about 
4.5 kb, and contain no viral sequences in addition to ITRs (Verma and Weitzman 2005). The 
transgene is cloned between the ITRs, and vectors are produced by providing necessary AAV 
structural proteins and helper virus functions in trans. rAAVs lack Rep proteins and become 
therefore inefficiently integrated into the transduced cell genome. If integration occurs, it takes 
place at random genomic locations and in ribosomal DNA repeats (Miller et al. 2005). Pre-
existing chromosomal breaks often serve as vector ISs, and integration is frequently associated 
with chromosomal rearrangements, insertions and deletions (Deyle & Russell 2009). Integrated 
vectors are often found as concatamers (Miller et al. 2004; Miller et al. 2002). Although long-
term transgene expression can be obtained from non-integrated vectors that can persist in 
nuclei for several months, integration of the vector into the genome represents a source for 
genotoxicity. Indeed, rAAV integration has been linked to the occurrence of hepatocellular 
carcinoma in mice (Donsante et al. 2001; Donsante et al. 2007), although this finding was 
contradicted in another study (Li et al. 2011a). 
rAAVs have been used in a number of Phase I and Phase II clinical trials targeting different 
diseases such as muscular dystrophy, hemophilia, Parkinson's disease and macular 
degeneration. Of the 92 clinical gene therapy trials conducted with rAAVs, 6 have reached 
phase III (http://www.abedia.com/wiley/index.html.) Remarkably, the first gene therapy 
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product on the European market today is based on rAAVs (European Medicines Agency 2012). 
The limited packaging capacity of the vectors, together with issues related to vector production, 
tissue tropism, possible genotoxicity and pre-existing neutralizing antibodies, still need to be 
addressed if rAAVs are to be made even better applicable for use in different gene therapy 
treatments (Asokan et al. 2012).  
2.4.2 Non-viral vectors  
Non-viral vectors consist of DNA or RNA molecules that are transfected into cells with the aid 
of complexion with specific DNA carrying moieties, such as lipoplexes, or introduced with the 
aid of physical methods such as electric current (electroporation; Verma and Weitzman 2005). 
As mentioned earlier, their large-scale production is simple and easy, but the poor efficiency of 
in vivo gene transfer may limit the usefulness of non-viral vectors for gene therapy in certain 
applications and target tissues. The main classes of integrating non-viral vectors are described 
below.  
2.4.2.1 Recombinases and phage integrase vectors 
Several recombinases and integrases e.g. of phage origin are routinely used in molecular 
biology laboratories as molecular cloning tools. These systems can also be harnessed for the 
integration of desired sequences to the human genome when delivered into cells as expression 
constructs, mRNA or proteins (Voigt et al 2008). These enzymes generally catalyze the site-
specific attachment of a DNA molecule bearing specific enzyme recognition or attachment sites 
(att-sites) into another DNA molecule that contains similar sites. Att-site –flanked genes of 
interest are cloned into donor constructs, which are delivered into cells along with the source 
for the enzyme. The drawbacks of these kinds of systems are that target att-sites may not be 
naturally present in the human genome but must be introduced with another integrating vector, 
which may cause insertional mutagenesis. Certain recombinases, such as Cre from 
bacteriophage P1 (Abremski and Hoess 1984), have reversible activity and can be used for the 
dissection of already integrated genes out of the genome (Papapetrou and Sadelain 2011). Other 
recombinases suggested as tools for site-specific gene insertion, such as the integrase from 
phage PhiC31, have natural pseudo-att-sites in the human genome.  Expression of the enzyme 
is however associated with chromosomal aberrations (Liu et al. 2009), and the large number of 
potential genomic recombination sites can diminish the specificity of integration (Chalberg et al. 
2006), leading to negligible improvement with regard to genotoxicity when compared to other 
integrating vector types. However, there are serine recombinases that are amenable to DNA-
specificity reprogramming, and these may prove useful for genome modification studies in the 
future (Gaj et al. 2011; Gordley et al. 2009). 
2.4.2.2 Transposon vectors 
Transposons are mobile genetic elements which code for an enzyme needed for DNA mobility 
(the transposase) and catalyze the attachment of terminal repeat-flanked transposon sequences 
to new genomic locations. Transposons are divided into DNA transposons and RNA 
transposons, and the different transposon families function through different mechanisms (Ivics 
et al. 2009). The DNA cut-and-paste transposons encode for a transposase, which cleaves the 
transposon from one location and inserts it into another location. The retrotransposons, in 
contrast, rely on cellular enzymes for mobility, and resemble retroviruses in that their life cycle 
involves an RNA intermediate, which is reverse transcribed to a cDNA copy that is transposed. 
About 45% of the human genome consists of transposable elements, but L1, SVA and AluY 
transposons are the only active transposons in humans today (Lander et al. 2001; Burns & Boeke 
2012).   
Transposons can act as integrating non-viral vectors when the transposase is provided in 
trans, and the GOI is cloned between terminal repeats. The majority of gene transfers with a 
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gene therapy focus have been conducted using the Sleeping Beauty transposon, which is a 
reactivated eukaryotic transposon found in the fish genome (Ivics et al. 1997). It integrates into 
AT-sequences with a rather random pattern in the genomic scale (Berry et al. 2006; Wilber et al. 
2011). Transposition favors active genomic areas, and has no preference for gene regulatory 
areas or any other specific genomic annotations, albeit the results obtained from different cell 
lines are somewhat contradictory. Because the Sleeping Beauty has no preference for 
transcription units, it can be considered to be a safer vector than e.g. γRVVs with regard to 
inadvertent activation of cellular gene expression (Ivics et al. 2009).       
2.4.2.3 Hybrid vectors and vectorization of integrating non-viral vectors  
Due to the difficulties of in vivo gene transfer using plasmid-based nonviral vectors, different 
approaches have been used to improve their intake by cells. Viral vectors with good 
transduction efficiencies for different cell types can be used to improve the cellular delivery of 
non-viral vectors, termed vectorization or hybrid vector generation. IDLVs have been used to 
vectorize the Sleeping Beauty transposons, recombinases and nucleases of different origins 
(Qasim et al. 2010). In most of these approaches, the viral vector contains either the donor or the 
catalyst-encoding sequences. Enzyme-encoding sequences are separated from the donor 
constructs to avoid their inadvertent integration into the genome, which could lead to transgene 
mobility and genomic instability. The two, or in some cases three, different vectors deliver the 
components required for integration into the nuclei of transduced cells, where they become 
transiently expressed. Finally, the integration/ recombination/ transposition catalysts promote 
the insertion of donor sequence into the cellular genome.  
The drawbacks of such a delivery system are the difficulty of ensuring correct co-
transduction of the different vectors into the same cell and issues related to optimal timing of 
catalyst expression versus donor sequence presence in the nucleus. As IDLVs can promote 
transgene expression for extended periods of time in non-dividing cells (Wanisch & Yáñez-
Muñoz 2009), prevailing expression of the enzyme components may also pose problems even in 
the absence of their integration. Moreover, the low but existing level of background integration 
of IDLV-delivered expression constructs (Ebina et al. 2012) poses a safety risk with this 
approach. As a solution, the catalyst could be transfected or transduced as mRNA, or delivered 
by protein transduction. Indeed, the Vpr trans-packaging method has already proven useful for 
the cellular delivery of a meganuclease (Izmiryan et al. 2011), but the drawbacks associated 
with Vpr may discourage its use on a larger scale. An optimal delivery system for integrating 
non-viral vectors would be capable of transducing all the necessary components within one 
vector particle, without any risk for inadvertent integration of unintended sequences or causing 
any undesired side effects on target cells.     
In addition to vectorization of integrating non-viral vectors, hybrid vectors can be based on 
different viruses. Often the aim is to enhance integration of an inherently non-integrating virus 
vector (Verma and Weitzman 2005). In addition, the integration specificity of one vector can be 
modified with this strategy, for example by transferring the MLV IN coding region into HIV, 
which caused the hybrid to integrate with a specificity close to that of MLV (Lewinski et al. 
2006).  
2.4.3 Harnessing DNA double strand breaks for targeted genome modifications 
Of the different strategies developed for targeted transgene integration, those based on 
generating site-specific DNA double strand breaks (DSBs) to enable precise gene insertion are 
currently undergoing most intensive development. DSBs represent the most severe form of 
genotoxic stress and must therefore be efficiently and reliably repaired to maintain the integrity 
of genomic DNA (Lewin 2004). Two main pathways are used in higher eukaryotes to repair 
DSBs: homologous recombination (HR) and non-homologous end joining (NHEJ) (reviewed in 
Hartlerode and Scully 2009). The HR pathway requires the presence of a homology-containing 
donor molecule, and is therefore generally restricted to the S or G2 phases of the cell cycle. 
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NHEJ is active throughout the cell cycle but is of particular importance during G0-, G1- and 
early S-phase of mitotic cells. HR is a complex pathway that involves several cellular proteins, 
and results in error-free recovery of the cleaved site. NHEJ, on the other hand, is a fast process 
that involves fewer protein complexes but is error-prone and often results in small insertions or 
deletions (“indels”) at the repaired site (Hartlerode and Scully 2009). NHEJ is the predominant 
DSB repair pathway in non-cycling cells. The balance between the two pathways is dependent 
on the cell type and the chromosomal location of the DSB, but it is possible to favor one or the 
other by influencing specific factors that are needed in these partly overlappig pathways 
(Brandsma & Gent 2012). 
HR has been traditionally used to generate transgenic animals, but the low spontaneous 
frequency of gene targeting using plasmid vectors, which is only in the order of 1X10-6, 
precludes its use for genetic engineering of cells for gene therapy purposes (Wirt and Porteus 
2012). A DSB generated at a genomic locus is, however, able to enhance by several orders of 
magnitude the probability of insertion of exogenous templates to desired genomic sites (Urnov 
et al. 2010). When the exogenous (donor) DNA molecule is designed to contain homology arms 
flanking the cleaved site, insertion of desired sequences can be accomplished through 
homology directed repair (HDR) of the DSB. These sequences can consist of entire transcription 
units or be made up of homology-flanked small point mutations that can correct the disease-
causing mutations, this is called genome editing. A third option would be insertion of a 
transgene in-frame with an endogenous gene without adding a promoter, which has the 
advantage of preserving natural expression levels of introduced genes. In the absence of a 
donor molecule, targeted disruption of cellular genes can be obtained through the imprecise 
action of NHEJ at the DSB (Perez-Pinera et al. 2012; Urnov et al. 2010; Wirt and Porteus 2012). 
The different DSB-dependent pathways have now been successfully exploited in modifying the 
genomes of many different cell types. Moreover, targeted gene disruption through NHEJ has 
been utilized in phase I and II clinical gene therapy trials aiming at the eradication of HIV-1 in 
infected patients (clinicaltrials.gov; http://www.sangamo.com/pipeline/sb-728.html). 
2.4.3.1 Sequence-specific nucleases  
Many types of nucleases can be used for generating a site-specific DSB to prime targeted gene 
insertion through HR, the major requirement being a sufficiently long recognition site to 
optimally present a unique locus in the human genome (Wirt and Porteus 2012). REs with such 
long recognition sites are called meganucleases. In nature, these enzymes are mainly found 
among the intron-encoded homing endonucleases. The DNA-recognition and cleaving 
characteristics of certain natural meganucleases can be modified to generate proteins with a 
desired DNA-cleaving specificity (Grizot et al. 2009). However, the development of designer 
zinc finger nucleases (ZFNs), whose DNA-specificity can be rather flexibly modified, was an 
important milestone in opening new avenues for targeting an unparalleled array of genomic 
loci for transgene insertion (Kim et al. 1996; Li et al. 1992).  
ZFNs are small dimeric proteins with a natural zinc-finger DNA binding domain attached to 
a nuclease domain derived from the FokI enzyme (Urnov et al. 2010). One important feature of 
the ZFN architecture is that DNA cleavage requires nuclease dimerization: two different ZFNs 
are designed to bind the adjacent half-sites (left and right) of the target sequence. Upon 
dimerization, ZFNs are able to recognize and cleave sequences of 9–18 bp in length. Despite the 
requirement for dimerization, ZFNs can form enzymatically active homodimers which have 
inferior target site specificity in comparison to heterodimers (Gabriel et al. 2011; Pattanayak et 
al. 2011). The resulting off-target activity and genotoxicity of ZFNs can be reduced by using so 
called obligatory heterodimer-ZFNs, which only cleave target DNA upon correct dimerization 
of the left and right counterparts on the recognition site (Miller et al. 2007).  
More recent players in the DSB-inducing enzyme field are the transcription activator-like 
effector nucleases (TALENs), which utilize the natural high-specificity DNA-binding domains 
of TAL effectors for DNA recognition and similar to the ZFNs, FokI for DNA cleavage (Li et al. 
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2011b). TALENs have shown better specificity in DNA cleavage and reduced genotoxicity when 
compared to ZFNs (Mussolino et al. 2011) but they are much larger in size and more difficult to 
vectorize due to the repeating nature of the DNA binding domain structure (Holkers et al. 
2012).   
Recently, a natural RNA-guided DNA nuclease system has been successfully harnessed for 
specific DSB generation in mammalian cells (Cong et al. 2013; Jinek et al. 2013; Mali et al. 2013). 
These CRISPR (clustered regularly interspaced short palindromic repeat)/Cas (CRISPR-
associated protein) systems are essential components of nucleic-acid-based adaptive immune 
systems of bacteria and archaea, and resemble the short interfering RNA  (siRNA) defense 
mechanisms found in eukaryotes (Wiedenheft et al. 2012). The active Cas nucleases associate 
with guiding and trans-acting RNA molecules and cleave a DNA fragment that is 
complementary to the exposed part of the guiding RNA molecule. Also the CRISPR-systems 
seem to be capable of multiplex engineering of human cell genomes, as they are able to catalyze 
site-specific DNA cleavage, enhance HR-dependent integration of DNA molecules into DSBs, 
promote gene disruption through NHEJ and induce deletions of larger genomic regions in 
different human cells (Cong et al. 2013; Jinek et al. 2013; Mali et al. 2013). The efficiency of this 
system seems to be comparable to the ZFN or TALEN based methods, but adjusting its 
specificity towards new target sequences should be easier because it only requires new designs 
of the guiding RNA molecules. However, similar to the other nuclease systems, the efficiency 
and specificity of RNA-guided DNA cleavage could be further improved (Cong et al. 2013; Mali 
et al. 2013). 
2.4.3.2 Site-specific integration and genome editing  
In practice, site-specific integration of homology-containing donors to a genomic site requires 
the transfection or transduction of at least two constructs into the target cells, the nuclease-
encoding construct and the donor construct (Porteus and Carroll 2005). The left and right 
counterparts of the ZFNs and TALENs are divided into separate expression constructs, which 
raises the number of transferred molecules to three.  Integration of the endonuclease cassette 
into the genome is undesirable, as its constant expression could result in severe genomic 
instability. Linear donor constructs are preferred substrates for HR but also circular plasmid 
donors can be functional. The homology arms flanking the GOI required for HR to occur are 
typically about 750 bp each, but microhomologies of as little as 50 bp can be used to direct an 
insertion into a DSB (Orlando et al. 2010). Nuclease expression constructs and donor sequences 
have been mainly transfected into cells as plasmid DNA, but there are many reports describing 
the use of the more versatile and efficient viral vectors and IDLVs to deliver the necessary 
components into cells (Cornu and Cathomen 2007; Gabriel et al. 2011; Holkers et al. 2012; 
Izmiryan et al. 2011; Lombardo et al. 2011; Lombardo et al. 2007; Okada et al. 2009).  
The fidelity and safety of cleavage-assisted integration and genome editing depends on the 
cellular pathway used for DSB repair, and on the specificity of the nuclease in question. An 
excess of nucleases can result in off-target cleavage and subsequent genotoxic effects (Perez-
Pinera et al. 2012; Porteus and Carroll 2005). Although HR is the preferable DSBR pathway for 
transgene integration due to its high fidelity in maintaining the original DNA sequence at the 
site of integration, the parallel action of NHEJ needs to be taken into account to minimize 
undesired generation of indels. NHEJ not only joins free ends of cleaved DNA to each other, but 
can also result in the inclusion of foreign sequences lacking homology to the repaired site, 
sometimes associated with additional mutations (Gabriel et al. 2011). Donor sequences may also 
become inserted at the cleaved site as concatamers (Izmiryan et al. 2011; Lombardo et al. 2011; 
Lombardo et al. 2007), which can result in undesired expression levels of the transgenes and 
disrupted transcriptional balance of nearby cellular genes through multiple insertion of 
promoters and enhancers. These phenomena may decrease the safety of the DSB-enhanced gene 
integration strategy, and likely need to be better controlled before there can be any wider use of 
this method in clinical gene therapy. One option to increase the level of HDR over NHEJ is to 
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use single-strand break –generating nickases in place of nucleases, as single-strand breaks seem 
to be favorably repaired through HDR (reviewed in Perez-Pinera et al. 2012).   
Solutions to avoid off-target activity of nucleases include using enzymes with high sequence 
specificities and limiting the activity window of nucleases to reduce the time for off-target 
events (Wirt and Porteus 2012). Small molecule regulation of ZFN protein levels has already 
proven to be useful for the reduction of cytotoxicity (Pruett-Miller et al. 2009). In addition, 
optional delivery methods, such as mRNA transfection and protein transduction could be used 
for the same purpose.  
The efficiency of targeted integration and genome editing events varies substantially 
between different nucleases, genomic target sites, target cells types and other experimental 
variables. Table 2 summarizes targeting efficiencies obtained in studies that have utilized IDLVs 
or LVVs for the delivery of nucleases and donor molecules with the aim of site-specific gene 
integration. The AAVS1 locus has been postulated as a GSH because no known diseases 
associate with the natural integration of AAVs into this locus. The C-C chemokine receptor type 
5 (CCR5) gene encodes a major co-receptor for HIV-1, and individuals carrying homozygous 
mutations in the gene have not been characterized by any major pathology but are resistant to 
CCR5-tropic HIV-1 infection (Liu et al. 1996). Over 100 mutations in the IL2RG gene are found 
in SCID-X1 patients, and in these patients it could present a feasible target for the integration of 
a functional copy of the gene, or for editing a disease-underlying mutation (Sadelain et al. 2011; 
Wirt and Porteus 2012).     
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Table 2. Site-specific integration with LVV or IDLV-associated nucleases.  
 
 
 
 
 
 
* As reported in publication. IDLV, integration deficient lentivirus vector; IDLV-N; nuclease-
expressing IDLV; IDLV-D, donor molecule-carrying IDLV; LVV-N, nuclease-expressing lentivirus 
vector; Ad, adenvirus vector; B-lbc, B-lymphoblastoid cells; Lbc, lymphoblastoid cells; HPC, 
hematopoietic progenitor cell; Rep.CL, reporter cell line; HUES, human embryonic stem cells; iPSC, 
inducible pluripotent stem cells; NSCs, neural stem cells; IL2RG, Interleukin 2 receptor gamma 
gene; CCR5, chemokine receptor 5. 
 
 
 
 
 
 
Reference Vector  system Targ. 
protein 
Target Target cell Site-specific 
events* (%) 
  
Izmiryan et al. 2011 1 x IDLV (N+D) (Vpr-) I-SceI π10 locus Rep.CL 48 
IDLV-N (Vpr-I-SceI) + IDLV-D (Vpr-) I-SceI 33 
IDLV-N + IDLV-D I-SceI 22
Lombardo et al. 2007 2 x IDLV-N + IDLV-D ZFN IL2RG K-562  3.4 ± 1,0
 Lbc 1.8 ± 0.7
 Lbc 2.9-6
 ZFN CCR5 K-562 35 ± 10 
 Jurkat 39 ± 9
 Lbc 3 ± 1.7
 CD34+ HPC 0.06 ± 0.02
 HUES-3 and -1 3.5 ± 1.1
Lombardo et al. 2011 2x IDLV-N + IDLV-D ZFN AAVS1 B-lbc ~9.5-12
 HepG2  ~4-19
 NSCs 0.06
 iPSCs <0.7
2x IDLV-N + IDLV-D ZFN CCR5 B-lbc ~7-11.5
 HepG2  ~2-15
Ad5/35-N + IDLV-D ZFN AAVS1 primary human  
T lymphocytes 
~1.2-3.8
 CCR5 ~4.5
Cornu and Cathomen 
2007 
IDLV-N +IDLV-D I-SceI I-Sce I site Rep.CL ≤0.8
 Rep.CL (2) 8-12
 Rep.CL 0.4
LVV-N + IDLV-D I-SceI I-Sce I site Rep.CL ≤ 5 
 Rep.CL 2.3
 Rep.CL (2) 1.1-1.9
Gabriel et al. 2011 2x IDLV-N +IDLV-D ZFN1 IL2RG K-562  2.7 ± 0.3
 ZFN2 IL2RG K-562  26.1 ± 3
 ZFN1 CCR5 K-562  27.1 ± 2.1
 ZFN2 CCR5 K-562  28.2 ± 1.4
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2.5 RIBOSOMAL DNA AND NUCLEOLI 
2.5.1 rDNA structure and function 
The protein-encoding genes of eukaryotes are transcribed into mRNA molecules by the RNA 
polymerase II, and mRNAs are translated into proteins by ribosomes. Ribosomes are 
ribonucleoprotein complexes that consist of four different ribosomal RNA (rRNA) molecules 
and multiple proteins. The genes encoding for the rRNA molecules reside in a clearly defined 
nuclear body, the nucleolus (Boisvert et al. 2007; Sirri et al. 2008). Nucleoli are essentially 
composed of repetitive rRNA gene clusters, collectively called the ribosomal (r)DNA, and the 
machineries needed for rRNA gene transcription and transcript processing. In humans, rDNA 
is found in the short arms of the five acrocentric chromosomes: 13, 14, 15, 21 and 22 (Figure 7). 
Each diploid human cell has about 600 copies of the tandemly repeating 43kb rRNA genes 
(Stults et al. 2008). Despite its repeating nature, rDNA is not subject to noticeable mitotic 
recombination (Killen et al. 2009). During meiosis, however, rDNA undergoes marked 
recombination, resulting in the appearance of so- called rDNA fingerprints which are specific 
for each individual (Stults et al. 2008). rRNA genes are highly conserved in all eukaryotes. 
 
Figure 7. The location and organization of rRNA genes and the rDNA. The acrocentric human 
chromosomes bearing rDNA are shown at the top. rDNA consists of repeating rRNA gene units 
(center), each of which contains the 45S rRNA gene with its individual rRNA counterparts (bottom). 
rDNA, ribosomal DNA; rRNA, ribosomal RNA; IGS, intergenic spacer; ETS, external transcribed 
spacer; ITS, internal transcribed spacer. 
 
With the exception of the 5S rRNA, which is produced from a cluster of repeated 2.2-kb 
genes on chromosome 1q42 (Sørensen et al. 1991), the conserved genes encoding for all rRNA 
molecules are found within one transcription unit (Lewin 2004).  This 45S rRNA gene is flanked 
by non-transcribed intergenic spacers (IGS), which separate the individual transcription units 
from each other (Figure 7). Each rRNA gene is additionally flanked by external transcribed 
spacer sequences (5’ETS and 3’ETS), and interspaced by internal transcribed spacers (ITS1 and 
ITS2). These sequences are included in the large 45S primary transcript produced by the RNA 
polymerase I. Post-transcriptional processing of the 45S precursor separates the external and 
internal spacer sequences from the individual rRNA molecules that form the active ribosomes.  
The 28S, 5.8S and 5S rRNA molecules form the large subunit of the mature ribosome, whereas 
18S rRNA makes up the small subunit. The active ribosomes are formed when the two subunits 
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with their associated protein components unite in the cytosol and initiate mRNA translation 
(Boisvert et al. 2007; Sirri et al. 2008). 
2.5.1.1 Nucleolar substructures and ribosome biogenesis 
Transcription of the rRNA genes and their subsequent processing inside a nucleolus represent 
different subcompartments that can be identified by transmission electron microscopy. Nucleoli 
are surrounded by a dense shell of inactive heterochromatin, which constitutes mainly from 
different repetitive DNA sequences, transcriptionally repressed genomic sequences and the 
IGSs (Boisvert et al. 2007). The lightly staining center of the nucleoli, called the fibrillar center 
(FC) (Figure 8), contains the expressed rRNA genes in an open conformation. A part of the 
rRNA genes are transcribed and accessible to transcription factors at all times. RNA polymerase 
I-driven transcription occurs either in the FC or at the boundary between the FC and the dense 
fibrillar component surrounding it. Precursor rRNA molecules become spliced and are 
modified by small nucleolar ribonucleoproteins in the dense fibrillar component, which also 
contains the processing intermediates. The nucleolar protein fibrillarin has important roles in 
the early steps or 45S rRNA processing and it can be used as a marker for the dense fibrillar 
component (Boisvert et al. 2007). Ribosome assembly begins in the granular component, where 
pre-ribosomal particles in various stages of maturation can be seen as granules in the 
transmission electron microscope. Ribosome maturation is completed in the cytoplasm where 
the two subunits associate. 
Figure 8. A schematic of the nucleolus and the structures within it. The different subcompartments 
of the nucleolus are shown, with rRNA gene transcription taking place at the border of the fibrillar 
center and the dense fibrillar component. 
 
Nucleoli and the ribosomes they produce are indispensable for cells as they are responsible 
for the cell’s entire protein synthesis. The functional status of a nucleolus is directly linked to its 
morphology, which can be affected by external stimuli (Bártová et al. 2010). Cellular 
immortalization may increase the number of active nucleoli in cells and their number also 
varies during the normal course of the cell cycle (Hernandez-Verdun 2011). In addition to 
ribosome biogenesis, nucleoli have several roles in cell-cycle control, aging, transcriptional 
suppression of non-rDNA genes, nuclear architecture, metabolism and viral defense or 
replication (Boisvert et al. 2007). Alterations in the functionality of nucleolar components are 
linked to many disease types, ranging from premature aging to cancer.  
2.5.1.2 Nucleolus-associated domains 
The genomic DNA within the nucleus is not randomly distributed, but certain chromosomes 
and parts of chromosomes tend to be found organized into distinctive spatial organizations 
including chromosomal territories and areas with functional associations (Tanizawa and Noma 
2012 and references therein). Moreover, specific genomic sequences or elements co-localize 
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repeatedly in parallel with the physical features of the nucleus, such as the nuclear lamina, and 
nuclear bodies. Nucleoli are mostly made up of rDNA, but other chromatin sequences also 
surround the nucleolar surface and may even loop into it. These kinds of nucleolus-associated 
domains (NADs) have been characterized in detail rather recently, and it is now known that 
about 4% of the non-rDNA-containing genome is associated with nucleoli (Németh et al. 2010). 
Specific sequence features are enriched in NADs, including repetitive DNA sequence elements, 
AT-rich sequences and loci shown to have low levels of gene expression. In addition, specific 
gene and gene families are found in NADs: transcriptionally active 5S rRNA genes, transfer 
(t)RNA genes  and members of the zinc-finger protein, olfactory receptor, defensin and 
immunoglobulin gene families (Koningsbruggen et al. 2010; Németh et al. 2010). Some NADs 
overlap with lamina-associated domains, which cover almost half of the genome (reviewed in 
Németh and Längst 2011). NADs also contribute to forming the dense heterochromatic outer 
shell of nucleoli.  
2.5.1.3 Insertion sequences within the rDNA  
Specific genetic elements have been termed selfish genes or molecular parasites owing to their 
ability to replicate and multiply within the host genome. In addition to the well-known 
transposons, these elements include intron-encoded homing endonuclease (HE) genes and 
inteins (protein introns). At least five unique structural families of HEs have been identified 
with two families being found in eukarya and archaea (Belfort and Roberts 1997; Chevalier and 
Stoddard 2001). HE genes and the mobile intron sequences encoding for them are frequently 
found in conserved coding regions within essential host genes, including the tRNA genes and 
rRNA genes of many organisms. Due to its repetitive nature, rDNA contains numerous 
potential sites for new insertions of the parasitic element. In addition to HEs, also the eukaryotic 
R2 retrotransposon, found in the genomes of many animal genera, can target a single site in the 
28S rRNA genes (Kojima and Fujiwara 2005). 
Mobile introns are divided into two classes based on their different homing mechanisms. The 
homing process can be defined as the transfer of an intervening genetic sequence to a 
homologous host gene that lacks the same element (Belfort and Roberts 1997).  Group I HE and 
intein genes propagate through generating DSBs in alleles that lack the intervening sequence. 
The cleavage is catalysed by the HE protein, the reading frame of which is embedded in the 
mobile intron sequence. The generated cut is repaired via HR by the host DNA repair 
machinery, using the allele carrying the HE intron as a template. Similar to exogenous gene 
insertion using designer nucleases, this process leads to the copying of a new, in this case a 
parasitic, element into the previously empty allele. The homing mechanism of mobile group II 
introns, also called retrohoming, is more complex and involves additional activities of the HE 
gene-encoded protein as well as endonuclease function (Chevalier and Stoddard 2001; Marcaida 
et al. 2010). 
2.5.2 The homing endonuclease I-PpoI 
I-PpoI is a small 18 kDa dimeric intron-encoded HE whose gene is found in the rDNA of the 
slime mold Physarum Polycephalum (Muscarella et al. 1990). It belongs to His-Cys HE-family, 
and has a 15 bp core recognition and cleavage site, which resides in the 28S rRNA gene of all 
eukaryotes (Flick et al. 1998; Mannino et al. 1999). Additional I-PpoI cleavage sites localizing to 
the non-ribosomal chromosomes of the human genome have been described rather recently 
(Berkovich et al. 2007; Wen et al. 2012; Gandhi et al. 2012; this work [II]). The enzyme is also 
capable of cleaving degenerate versions of the original CTCTCTTAAGGTAGC recognition 
sequence, and it can tolerate substitutions at multiple base locations (Wittmayer et al. 1998).  
High-level I-PpoI expression in human and yeast cells is toxic, probably owing to the many 
cleavage sites present in the cellular genomes (Muscarella & Vogt 1993; Monnat et al. 1999). 
Surviving cell populations that were resistant to further I-PpoI-induced DSBs and cytotoxicity 
were, however, obtained after I-PpoI intron transfection in yeast (Muscarella & Vogt 1993; Lin & 
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Vogt 1998; Lin & Vogt 2000). In these cells, the original I-PpoI recognition sites had become 
mutated, owing to mistakes during DNA repair mechanisms, or were interrupted by intron 
homing to the 28S rRNA target site. All of the yeast’s approximately 150 rDNA repeats located 
on one chromosome can accommodate the natural I-PpoI HE gene with moderate effects on 
cellular growth rates (Muscarella & Vogt 1993; Lin & Vogt 1998; Lin & Vogt 2000). In addition to 
encoding for the nuclease function, the I-PpoI HE gene transcripts contain ribozyme functions 
that enable early autocleavage of the HE gene-containing intron from precursor rRNA 
molecules (Rocheleau and Woodson 1995). If correct splicing of the intron sequence was 
disabled, then the yeast cell growth rates were severely compromised (Lin and Vogt 2000; Lin 
and Vogt 1998). Removal of the intervening intron sequences from precursor-rRNA gene 
transcripts was thus a prerequisite for the production of functional ribosomes in yeast.  
The rate and extent of I-PpoI site cleavage in human cells have been addressed in DSB repair-
related studies (Berkovich et al. 2007; Gandhi et al. 2012). It was demonstrated that a maximum 
of 30% of genomic I-PpoI sites can be cleaved after introducing the protein into human cells 
(Wen et al. 2012). This figure is in agreement with a previously obtained maximum level of  25% 
(Gandhi et al. 2012). The average levels of I-PpoI site cleavage of both the rDNA-embedded and 
the non-nucleolar sites seem, however, to be around 10% (Monnat et al. 1999; Gandhi et al. 
2012).  
2.5.3 rDNA as a genomic safe harbour for transgene integration 
The features that a genomic locus should possess to present a GSH were discussed in section 
2.2.2 (Papapetrou et al. 2011). The majority of sites proposed as GSHs and targeted for 
integration with different techniques do not fully meet these requirements, but loci suitable for 
transgene integration with respect to all of the proposed features have been identified 
(Papapetrou et al. 2011; Sadelain et al. 2011).  
Since rDNA presents a unique entity within the genomic DNA with respect to its physical 
and spatial properties, the criteria proposed by Papapetrou et al. (2011) cannot be easily applied 
to classifying it as a GSH. However, rDNA has many unique features that make it an appealing 
target for transgene integration. These include (i) its location in the short arms of the acrocentric 
chromosomes, which are physically separated from protein-encoding genes with oncogenic 
potential; (ii) the large number of rRNA genes, due to which complete loss of rRNA gene 
function through transgene integration is highly unlikely; (iii) rDNA-contained genes encode 
for rRNA molecules, which are unlikely to acquire harmful GOF mutations even after enhancer 
element insertion, and (iv) individual rRNA gene repeats are flanked by intergenic spacer 
regions, which have natural insulator functions (Van de Nobelen et al. 2010). Despite going 
through high-frequency recombination during meiosis (Stults et al. 2008) and being a 
recombination hotspot in cancer (Stults et al. 2009), rRNA gene cluster stability is normally very 
well preserved in mitotic cells (Killen et al. 2009). The repeating nature of rRNA genes is thus 
unlikely to have a negative impact on the stability of rDNA-inserted transgenes in healthy 
somatic cells. Due to all of the above mentioned characteristics of rDNA, it can be considered as 
a good candidate for a GSH, even though it fails to fully meet the criteria proposed for GSHs in 
the non-rDNA-related chromatin.  
 
2.6 ETHICAL ASPECTS OF GENE THERAPY AND INTEGRATING VECTORS 
The emergence of different SAEs after gene therapy treatments has increased public and 
professional discussion about the ethical aspects in gene therapy. The leukemia cases in the 
SCID-X1 trials (Table 1), among other SAEs of gene therapy, have highlighted the risks 
associated with gene therapy vectors, and raised a need for directions on how to prevent such 
cases from renewing. Gene therapy treatments are required to adhere to modifying only 
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somatic cells in order to avoid transmission of genetic alterations to next generations (Gonin et 
al. 2005). New candidate treatments are identified and studied in basic research, and the data 
describing the safety and efficacy of the product should be documented in compliance with the 
Good Laboratory Practices (GLP). Next, the disease model and the candidate treatment are 
examined in depth in preclinical models that preferentially mimic the human condition as 
precisely as possible. These studies can start from cell line studies, organ cultures and possibly 
human xenografts and preferentially extend in studies conducted in large animal models (King 
& Cohen-Haguenauer, 2008). At this stage, vector manufacturing processes should be scaled up 
and be in compliance with Good Manufacturing Practices (GMP) (Gonin et al., 2005). In 
addition, quality control, biosafety profiling and the risk assessments should be conducted 
appropriately. The risk-benefit balance will have to be convincingly justified in the final 
Investigational Medicinal Product Dossier in order to obtain positive opinions by the National 
Agencies and the Ethical Committee to start a clinical trial. Ethical consideration at the clinical 
study phase include weighing the risk-benefit balance of the treatment, the fairness in selecting 
patients for research, assuring proper informing of patients about the expected benefits and 
outcomes of the treatment before the process of the informed consent to experimental 
treatments, deciding the optimal time points of clinical intervention, and others.   
Today, the variables that contribute to the genomic risk associated with insertional 
mutagenesis in gene therapy are better characterized than at the time when the first SCID-X1 
trials were initiated (Biasco et al. 2012). Although many factors have been identified that 
contributed to the onset of leukemia following the ILR2G gene transfer trials, the development 
of SAEs has proven to be highly context-dependent (Kustikova et al. 2010; Rivière et al. 2012). 
Therefore, gene therapy that involves transgene integration unavoidably presents a risk for 
harmful genome modifications, as the factors underlying SAE development are difficult to 
predict.  It needs to be carefully evaluated whether the potential for obtaining generalizable 
knowledge from a gene therapy trial,  and in some cases also the clinical benefit that a patient 
may gain from the experiment, will exceed  the risks associated with transgene integration 
(King & Cohen-Haguenauer, 2008).   However, it is difficult to define the acceptable levels of 
risk in gene therapy treatments, and an open question remains on who decides whether the 
potential benefits exceed the risks (Deakin et al. 2009). In addition, disproportionate risk-
aversion in clinical gene therapy research may stifle the development of better treatments for 
many conditions. 
The risks related to a given gene therapy treatment should be communicated with patients 
and clinical trial participants thoroughly during the informed consent process, and all 
possibilities should be used to minimize the potential for harmful genomic modifications. 
Advisable issues to consider in order to minimize the risk for insertional mutagenesis and 
adverse effects include: engineering expression constructs that avoid enhancer interactions or 
fusion transcript production; careful analysis of a vector’s integration pattern and its 
confirmation in large animal studies to reveal the potential for genotoxicity; using vectors with 
as safe integration profiles as possible, including a more neutral or a safer integration pattern 
with regard to cancer-related genes and gene regulatory areas; targeting cells that lack a 
sustained replicative potential; and long-term follow-up of patients to monitor the occurrence of 
delayed adverse effects (King and Cohen-Haguenauer 2008; Kustikova et al. 2010; Rivière et al. 
2012). Guidelines are available for scientist about the necessary steps of genotoxicity testing and 
monitoring in both the preclinical and clinical phases of new drug development (U.S. 
Department of Health and Human Services Food and Drug Administration 2012). These 
guidelines are necessary and help to improve the characterization of risks that new therapies 
have for undesired carcinogenic effects. 
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3 Aims of the Study 
 
The aim of the study was to test whether transgene integration could be targeted to ribosomal 
DNA using a fusion protein consisting of the HIV-1 integrase and the homing endonuclease I-
PpoI. Approaching the aim involved the following steps:  
 
 
1) Generating a method to incorporate HIV-1 integrase fusion proteins into third generation 
lentivirus vectors. 
 
2) Testing whether the developed cis-packaging method could be harnessed for lentiviral 
protein transduction by generating and characterizing different IN-fusion protein—
carrying vectors and virus-like particles 
 
3) Characterizing the cellular integrome of IN-I-PpoI-fusion protein—containing vectors 
 
4) Determining the ability of IN-I-PpoI-fusion protein—containing lentivirus vectors to 
target integration into rDNA. 
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4 Materials and Methods 
4.1 MATERIALS 
The different materials used in the original publications I-III are listed in the tables below. The 
oligonucleotides are described in table 3; cell lines in table 4; different DNA constructs 
generated and used in table 5; antibodies in table 6; vectors and VLPs in table 7 and other 
reagents in table 8.  
 
The abbreviations used in the tables: U.P., unpublished work; CS, cytotoxicity studies; RIE, 
relative integration efficiency studies; IF, immunofluorescence studies; IS, integration 
site/targeting studies; IA, interaction studies; AI, apoptosis induction studies; BV, baculovirus 
vector; WB, western blot; DSB, DNA double strand break studies; NIH A.R.P., National 
Institutes of Health AIDS Research and Reference Reagent Program; Int., integration; DFC, 
dense fibrillar component; HSV, herpes simplex virus; TK, thymidine kinase; PGK, 
phosphoglycerate kinase promoter; GFP, green fluorescent protein; ChIP, chromatin 
immunoprecipitation. 
 
Table 3. Oligonucleotides used in this work.  
 
 
Table 4. Cell lines used in this work. 
 
Cel line Source Organism Description Used for Used in
A549 ATCC:CCL-185 human Lung carcinoma epithelial  CS III 
ARPE-19  CRL-2302 human Normal retinal pigment epithelial   CS III 
BT4C  R.Bjerkvig rat Rat glioma  CS III 
HEK 
293T/17 
ATCC: CRL-11268 human A derivative of the HEK293 
(293tsA1609neo) 
CS, LVV and VLP 
production 
I,II,III  
HeLa ATCC: CCL-2 human Cervical adenocarcinoma epithelial  CS, RIE, AI I,II,III 
HepG2 ATCC:HB-8065 human Hepatocellular carcinoma epithelial  CS III 
HUVEC Human umbilical cord human Umbilical cord endothelial cell CS, RIE I,III 
MRC-5 ATCC: CCL-171 human Normal lung fibroblast  CS, IF, IS, IA  II,III 
U-251  HTB-17 human Glioblastoma astrocytoma CS III 
U-87 HTB-14 human Glioblastoma astrocytoma CS III 
Sf-9 Invitrogen insect Spodoptera frugiperda; a clonal 
isolate of Sf21 cells (IPLB-SF21-AE) 
Protein production 
after BV transduct. 
II 
Oligonucleotide 
name 
Used for  Described in 
5’IN IN-fusion protein cDNA cloning I 
3’IN IN-fusion protein cDNA cloning I 
D64V forward IN-fusion protein cDNA cloning I 
D64V reverse IN-fusion protein cDNA cloning I 
p53 forward IN-fusion protein cDNA cloning I 
p53 reverse IN-fusion protein cDNA cloning I 
pRSET forward IN-fusion protein cDNA cloning I 
3’mCherry BspEI IN-fusion protein cDNA cloning I 
I-PpoI Forw IN-fusion protein cDNA cloning II 
I-PpoI Rev IN-fusion protein cDNA cloning II 
N119A Forw Generation of pMDLg/pRRE-IN-I-PpoIN119A II 
N119A Rev Generation of pMDLg/pRRE-IN-I-PpoIN119A II 
H78A Forw Generation of pMDLg/pRRE-IN-I-PpoIH78A III 
H78A Rev Generation of pMDLg/pRRE-IN-I-PpoIH78A III 
Pposite Cloning an I-PpoI site into pBluescript II 
rDNA 5’Ppo Cloning of a 345bp stretch of rDNA around the I-PpoI site into pGEM-T Easy III 
rDNA 3’Ppo Cloning of a 345bp stretch of rDNA around the I-PpoI site into pGEM-T Easy III 
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Table 5. DNA constructs generated and used in this work. 
 
 
 
 
 
Table 6. Antibodies used in this work. 
 
 
 
 
 
 
 
Plasmid  Source  Used for  Used and described 
in (+ Reference) 
pBluescript II  Stratagene/ Agilent 
technologies 
IN-fusion protein cDNA subcloning,  
cloning of pPposite  
I,II 
pLJS10  NIH A.R.P HIV-1 IN cDNA source I 
p53pBacCapIRed H-R. Kärkkäinen Source of p53 cDNA I 
pCNPpo6 R.J.Monnat Jr I-PpoI cDNA source  II (Monnat et al. 1999) 
pRSET-mCherry R. Tsien Source of mCherry cDNA I, (Shaner et al. 2004) 
pLV-GFP L.Naldini LVV production I,II,III 
pLV-GFP/KNR This work (I) LVV production (plasmid rescue) I 
pMD2G I. Verma LVV and VLP production I,II,III 
pRSV-Rev I. Verma LVV and VLP production I,II,III 
pMDLg/pRRE I. Verma LVV and VLP production I,II,III 
pMDLg/pRRE-IND64V This work (I) IDLV production I,II 
pMDLg/pRRE-IN-I-PpoI This work (II) LVV and VLP production II,III 
pMDLg/pRRE-IN-I-PpoIH78A This work (III) LVV and VLP production III 
pMDLg/pRRE-IN-I-PpoIN119A This work (II) LVV and VLP production II 
pMDLg/pRRE-INmCherry This work (I) LVV and VLP production I 
pMDLg/pRRE-IN-p53 This work (I) LVV and VLP production I 
pPposite This work (II) IN-I-PpoI activity studies II,III 
prEasy This work (III) IN-I-PpoI activity studies III 
pcDNA3.1 (+) Stratagene IN-mCherry expression plasmid I 
pGEM-T Easy Promega Cloning of prEasy III 
pEGFP-N1 Clontech Source of selection markers for pLV-
GFP/KNR 
I 
pBVboostFG O. Laitinen BV generation for IN-fusion protein 
expression in insect cells 
II, (Laitinen et al. 2005) 
Primary antibody Source Target Method Used in 
Antisera to HIV-1 IN, amino acids 23-34  
(Cat. No. #757) 
NIH A.R.P. HIV-1 IN WB I,II,III 
HIV-1 p24 Gag monoclonal antibody 
 (#24-4; Cat. No. 6521) 
NIH A.R.P. HIV-1 Gag-proteins WB I, U.P. 
Anti-HIV-1 p24 (AG3.0) NIH A.R.P HIV-1 Gag-proteins IF I 
Anti-HIV-1 RT (Cat. No. 6195) NIH A.R.P. HIV-1 RT (p51,p66) WB I 
NCL-p53-D07 (mAb D07) Novocastra Laboratories p53 WB I 
p53 (c-11):sc-55476 
Santa Cruz 
Biotechnology 
p53 WB I 
Rabbit polyclonal to Fibrillarin (ab5821) Abcam Fibrillarin (DFC) IF II,III 
Mouse IgG2b κ Alexa Fluor 647 Anti-H2A.X-
Phosphorylated (Ser139) Antibody 
BioLegend γH2A.X (DSBs) IF II,III 
Anti-RFP polyclonal  antibody 
MBL Medical & Biological 
Laboratories 
mCherry WB I 
Goat Anti-Rabbit IgG (H+L)–AP Conjugate Bio-Rad Laboratories Secondary Ab. WB I,II 
Goat Anti-Mouse IgG(H+L) -AP Conjugate Bio-Rad Laboratories Secondary Ab. WB I 
AF546 goat-anti-rabbit IgG(H+L) Invitrogen Secondary Ab. IF II 
AF488 goat anti-mouse IgG(H+L) Invitrogen Secondary Ab. IF I 
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Table 7. LVVs and VLPs generated and used in this work. With the exception of the plasmid rescue 
studies (in I) and in vivo HSV TK-GCV combination treatment (in III), all LVVs contained the PGK-
GFP transgene cassette (Figure 9).  
 
 
 
 
Table 8. Reagents and kits used in this work. 
 
 
 
 
 
 
 
LVV/ VLP name IN-modification / Description Used for  Used in 
IN-fusion protein LVVs 
LVV- wt IN None Control vector in most studies I,II,III 
LVV-IND64V D64V (Asp64 to Val) mutation in IN Integration deficient control II 
LVV-INp53 IN C-terminally fused to p53 AI I 
LVV-INmCherry IN C-terminally fused to mCherry Fluorescent labelling of LVVs  I 
LVV-IN-I-PpoI IN C-terminally fused to I-PpoI DSB; CS; IA II,III 
LVV-IN-I-PpoIH78A IN C-terminally fused to I-PpoIH78A DSB; CS; IS; IA III 
LVV-IN-I-PPoIN119A IN C-terminally fused to I-PpoIN119A DSB-control; IS; IA II 
Mixed multimer LVVs 
LVV-wt IN+IN-I-PPoIN119A wt IN and IN-I-PpoIN119A IS; IA II, U.P. 
LVV-wt IN+IN-I-PPoIH78A wt IN and IN-I-PpoIH78A DSB; CS; IS; IA III 
LVV-IND64V+IN-I-PoIN119A IND64V and IN-I-PpoIN119A IS; IA II, U.P. 
LVV-IND64V+ IN-I-PPoIH78A IND64V and IN-I-PpoIH78A DSB; CS; IS; IA III 
VLPs 
VLP-wt IN None A control VLP I, II 
VLP- IND64V D64V (Asp64 to Val) mutation in IN A control VLP I 
VLP-INp53 IN C-terminally fused to p53 AI I 
VLP-INmCherry IN C-terminally fused to mCherry Fluorescent labelling of VLPs I   
VLP-IN-I-PpoI IN C-terminally fused to I-PpoI DSB  II 
VLP-IN-I-PPoIH78A IN C-terminally fused to I-PpoIH89A DSB  III 
VLP-IN-I-PPoIN119A IN C-terminally fused to I-PpoIN119A DSB (control) II 
Reagent name Source Used for Used in  
Etoposide Lonza Apoptosis/ DSB induction  I 
Hydrogen peroxide Sigma DSB induction II 
jetPEI transfection reagent Polyplus-transfection Plasmid DNA transfection I 
p24 Immunosorbent assay PerkinElmer Life and 
Analytical Sciences 
LVV p24 CA-determination I,II,III 
CellTiter-Glo Luminescent cell viability assay Promega Cytotoxicity studies II,III 
Caspase-Glo 3/7 assay Promega Apoptosis assays I 
G418 InVivogen Eukaryotic cell selection I 
DNeasy tissue kit Qiagen Genomic DNA extraction I 
ChargeSwitch gDNA Mini and Micro Tissue 
Kit 
Invitrogen/ 
Life Technologies 
Genomic DNA extraction II 
ProLong Gold antifade reagent with DAPI Invitrogen/ 
Life Technologies 
Confocal microscopy sample 
preparation 
I,II,III 
QuickChange II XL Site-directed 
mutagenesis kit 
Stratagene Generation of mutations into 
packaging plasmids 
I,II,III 
GATEWAY Cloning reagents Gibco-BRL Cloning of His-tagged cDNAs into 
baculoviral genomes 
II 
BD TALON Metal affinity resin  BD Biosciences Recombinant protein purification from 
insect cells 
II 
Magna ChIP protein A magnetic beads Millipore ChIP studies III 
Ganciclovir (GCV)  HSV-TK combination treatment in the 
animal study 
III 
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4.2 METHODS 
The methods used in the original publications I-III are summarized in tables 9, 10 and 11. Each 
method is described in more detail in the designated original publication.   
 
Table 9. Different methods used in the production and characterization of IN-modified LVVs and 
VLPs. 
 
 
 
 
 
 
Method Description  Described 
in  
Used in 
IN-fusion protein cDNA 
subcloning 
Generating IN-fusion protein cDNAs in pBluescriptII I I,II 
IN-fusion protein cloning 
into pMDLg/pRRE 
Cloning of IN-fusion protein cDNAs into the LVV packaging 
plasmid pMDLg/pRRE 
I I,II 
pLV-GFP-KNR cloning Cloning of the plasmid rescue-compatible transfer construct I I 
Site-directed mutagenesis Generation of mutations into different IN proteins I,II I,II,III 
Cell culture Cell culture for various assays I,II,III I,II,III 
Plasmid DNA transfection Introduction of plasmid DNA into cells for LVV and VLP production 
and IN-mCherry detection 
I I,II,III 
Generation of LVVs, IDLVs 
and VLPs 
LVV, IDLV and VLP production I I,II,III 
LVV titering Determining the functional titers of LVVs and particle titers for 
LVVs and VLPs  
I I,II,III 
Western (immuno-)blotting Detection of LVV, IDLV,VLP and cell-contained proteins I,II I,II,III 
LVV and VLP transduction Transducing cells with different LVVs and VLPs in vitro and in 
vivo 
I,II,III I,II,III 
Apotosis studies Studying the induction of apoptosis in cells following different 
treatments 
I I 
Cytotoxicity studies Determining the viability of cells after different treatments II,III II,III 
Flow cytometry Detecting transgene-expressing cells after LVV transduction for 
RIE/ transduction studies and LVV titering 
I,II,III I,II,III 
RIE study Determining the relative integration efficiency of different LVVs II II, U.P. 
Immunofluorescence 
staining 
Preparation of cell, LVV and VLP samples for analysis with 
confocal microscopy 
I,II I,II,III 
Fluorescence microscopy Imaging of transgene expression in transduced cells I I 
Confocal microscopy Detailed imaging of LVVs, VLPs and cells processed by 
immunofluorescence staining 
I,II I,II,III 
Recombinant protein 
production 
Production of IN-proteins in Sf9 insect cells following baculovirus 
infection 
II II 
Recombinant protein 
purification 
Purification of HIS-tagged IN-proteins from insect cells II II 
In vitro cleavage assay 
using recombinant proteins 
Testing the DNA-cleaving ability and specificity of recombinant 
IN-proteins 
II II 
In vitro cleavage assay 
using LVV and VLP extracts 
Testing the DNA-cleaving ability and specificity of IN-proteins 
extracted from LVV and VLP preparations 
III III 
Detection of nuclear DSBs Detection of nuclear DNA double strand break sites by 
immunofluorescence and confocal microscopy 
II II, III 
38 
 
 
Table 10. Integration site analysis methods, bioinformatics methods and statistical methods used in 
this work. 
 
 
 
Table 11. In vivo methods used in this work. 
 
 
 
 
 
 
 
 
 
 
 
Method Description  Described 
in  
Used in 
Plasmid rescue Extraction of genomic vector integration sites using plasmid 
rescue 
I I 
LM-PCR Extraction of  genomic vector integration sites using ligation-
mediated PCR 
II II 
ChIP Chromosome immunoprecipitation, detection of protein-DNA 
contact sites 
III III 
ChIP-sequencing Protein-DNA interaction site study using ChIP sequencing III III 
DNA sequencing (Sanger / 
454) 
DNA sequence determination of DNA constructs, LM-PCR 
products and ChIP sequencing products 
I,II,III I,II,III 
Bioinformatics analysis of 
integration site data 
Processing and analysis of integration site data obtained from 
transduced cells 
I,II I,II 
Bioinformatics analysis of 
interaction site data 
Processing and analysis of  ChIP sequencing data obtained from 
transduced cells 
III III 
Analysis of integration sites 
in rDNA  
Analyzing integration sites within rDNA, which is not included in 
the annotated genome drafts 
II II 
Mapping of different 
elements into rDNA 
Localizing and mapping of rRNA gene elements and integration 
sites into an unannotated supercontig  
II II 
Statistical analysis One-way ANOVA and the Dunnet’s multiple comparison test I,II,III I,II,III 
Fisher’s exact test II II 
Chi-Square test II II 
Unpaired T test with Welch’s correction III III 
One-way ANOVA and the Bonferroni’s multiple comparison test III III 
Two-way ANOVA and the Tukey’s multiple comparison test III III 
Method Description  Described 
in  
Used in 
Experimental animals  Description of experimental animals and their handling III III 
Generation of subcutaneous 
tumours 
Subcutaneous injection of cancer cells into the backs of mice to 
generate subcutaneous tumours  
III III 
Blood sampling Drawing blood samples from mice for blood sample analysis III III 
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5 Results  
5.1 GENERATION AND CHARACTERIZATION OF IN-FUSION PROTEIN 
CONTAINING LENTIVIRAL PARTICLES (I-III) 
IN-I-PpoI fusion proteins were incorporated into LVVs in order to study their ability to direct 
integration towards the recognition sites of I-PpoI. These vectors and VLPs were additionally 
tested to determine the feasibility of the cis-packaging method for lentiviral endonuclease 
protein transduction. Point mutations were introduced into two codons located in the active site 
of I-PpoI. The asparagine 119 (N119) is important for efficient catalysis of DNA cleavage, and its 
mutation into alanine practically abolishes I-PpoI’s activity (0.0065% of the wild type enzyme 
activity) without causing a change to protein conformation (Mannino et al. 1999). N119 binds to 
the essential divalent metal cation Mg2+, required for cleavage of a substrate, and provides a 
hydrogen bond donor to the scissile phosphoryl group. LVVs carrying the IN-I-PpoIN119A fusion 
protein were designed for IN-catalyzed integration targeting studies, where nuclease-catalyzed 
cleavage of the target site would be unnecessary. The role of the histidine residue H78 in I-
PpoI’s active site is less clear than that of the N119’s, but its mutation to alanine results in a 52% 
decrease in endonuclease activity near to physiological pH (Mannino et al. 1999). IN fusions 
with I-PpoIH78A were used in both integration targeting studies and for endonuclease protein 
transduction. IN-p53 and IN-mCherry fusion protein-containing vectors were generated to 
study the potential extensions to the use of the cis-packaging method for protein transduction. 
VLPs containing different IN-fusion proteins were similarly generated to test protein 
transduction in the absence of concomitant gene transfer. 
5.1.1 The cis-packaging method (I) 
In order to be able to study the functionality of different HIV-1 IN fusion proteins in the context 
of third generation LVVs devoid of Vpr, IN-fusion protein cDNAs were cloned directly into 
vector packaging plasmid. In previous studies, IN-fusion proteins have been incorporated into 
replicating viruses or vectors directly from modified provirus sequences (Bushman and Miller 
1997; Katz et al. 1996) and using the Vpr trans-packaging strategy (Holmes-Son and Chow 2000; 
Holmes-Son and Chow 2002; Tan et al. 2006). Direct incorporation of IN-fusion proteins into the 
most recent gene therapy-grade LVVs has not been reported before.  
The packaging plasmid of third generation LVVs contains a RRE 3’ to pol (Fig. 9). Apart from 
this element efficient LVV production does not require the presence of HIV-1 accessory proteins 
or cis-acting elements downstream of the IN-gene. Such vectors were therefore rationalized to 
tolerate IN-fusion proteins better than the replicating viruses tested before, and provide a 
meaningful platform for integration targeting studies. The foreign protein cDNAs were cloned 
in-frame into the 3’end of IN in the vector packaging plasmid pMDLg/pRRE in order to drive 
the inclusion of IN-fusion proteins into vectors (Fig. 9). The natural stop-codon of IN was 
replaced by a restriction enzyme site to allow fusion-cDNA cloning. Because the Pol-
polyprotein is mainly processed into its counterparts (PR, RT and IN) only after virion budding 
(Pettit et al. 2004), one could anticipate that successful PTN extraction with this packaging 
strategy should not be limited by the premature activity of toxic proteins in producer cells. The 
packaging strategy was termed the cis-packaging strategy to distinguish it from the trans-
packaging strategy utilizing Vpr-fusion proteins.  
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Figure 9. Packaging plasmids for 3rd generation LVV production. The packaging plasmid on the left 
depicts the non-modified wild type (wt) IN-encoding, or the integration deficient IND64V-expressing 
plasmid. The modified packaging plasmid with IN-fusion protein cDNAs is shown on the right (the 
construct used for cis-packaging of heterologous proteins). The remaining three LVV production 
constructs are depicted in Figure 6.     
5.1.1.1 Mixed multimer vectors  
Fusions to the N or C terminus of IN decrease its enzymatic activities (Bushman & Miller 1997; 
Katz et al. 1996; Holmes-Son & Chow 2000; Holmes-Son & Chow 2002; Tan et al. 2006). 
However, integration activity of LVs or LVVs that contain an integration-defective IN can be 
rescued through trans-complementation, i.e. by providing an IN protein that harbours 
mutations at other inactivating amino acids, or lacks other domains than the original 
integration-defective IN (Gent et al. 1993; Fletcher et al. 1997; Liu et al. 1997). Trans-
complementation of IN function in the IN-fusion protein containing virions has been pursued 
with both the Vpr-packaging strategy (Holmes-Son & Chow 2000; Holmes-Son & Chow 2002; 
Tan et al. 2006) and by co-expressing wt IN molecules during virus production (Bushman & 
Miller 1997).  
In this thesis, vectors generated for integration targeting and endonuclease protein 
transduction studies were trans-complemented using equimolar amounts of two packaging 
plasmids in vector production: one containing the IN-fusion protein and the other carrying 
either the unmodified wt IN or an integration defective IND64V. Such mixed multimer vectors 
were generated to ensure integration proficiency of LVVs in a way that preserves the correct 
stoichiometry between Gag and Gag-Pol proteins in produced particles (Table 7). 
Third generation LVVs were produced in 293T producer cells via calcium phosphate 
precipitation of the four different production plasmids (Figure 6) in triple flasks, as described in 
Follenzi and Naldini (2002). Mixed multimer LVVs were produced by adding either of the trans-
complementing packaging plasmid to the transfection mix. VLPs were produced with the same 
method but omitting the transfer construct. The producer cell supernatant containing the LVVs 
or VLPs was collected two days after transfection, cleared by filtering and concentrated by 
ultracentrifugation. The different vectors and VLPs generated and studied in this work are 
presented in Table 7, and their characterization is described below. 
5.1.2 Fusion protein incorporation (I-III) 
Correct fusion protein incorporation was verified by immunoblotting. All of the tested IN-
fusion proteins were correctly packaged into LVVs and VLPs, as detected by both the antibody 
against HIV-1 IN (Fig 10. A) and fusion partner-specific antibodies, if the latter were available  
(Fig. 10 B). With the largest IN-fusion protein IN-p53 (85 kDa), the correct-sized fusion protein-
specific bands were least well visible in immunoblots (two right-most asterisks in Figure 10 A 
and B). Inclusion of the IN-fusion protein into vectors did not change the correct processing of 
the Pol-embedded RT proteins (p51 and p66), as exemplified with the IN-mCherry containing 
vectors (Fig. 10 C), nor the different forms of the Gag-polyprotein (Fig. 10 D). 
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Depending on the fusion protein, different levels of unspecific proteolytic degradation were 
observed. Whereas IN-I-PpoI became incorporated as the expected full-sized 50 kDa fusion 
protein, several protein sizes were detected in LVVs and VLPs containing IN-mCherry and IN-
p53 (Fig. 10 A and B). This degradation can result from sample preparation for western blot, 
from the activity of producer cell-derived cellular proteases, or from pseudo-recognition sites 
for the HIV-1 PR possibly present in the fusion protein. HIV-1 PR recognizes and cleaves a three 
dimensional protein structure rather than specific amino acid sequences in its target molecules 
(Prabu-Jeyabalan et al. 2002).  Potential pseudo-PR sites could therefore be predicted and 
eliminated from IN-fusion proteins prior to fusion cDNA cloning, if minimal degradation of the 
fusion partner would be desired in protein transduction protocols. 
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p24 (pg/ml)  TU/ml 
  n Mean SD  n Mean SD 
wt IN 9 1.45E+08 1.35E+08  9 3.26E+09 4.21E+09 
IND64V 4 3.08E+07 2.07E+07  4 1.05E+07 6.91E+06 
IN-I-PpoI 5 3.15E+08 1.78E+08  5 5.95E+08 1.19E+09 
IN-I-PpoIH78A 2 1.73E+08 5.94E+07 2 9.82E+07 1.28E+08 
IN-I-PpoIN119A 3 6.70E+07 6.12E+07  3 6.35E+07 8.88E+07 
IN-mCherry 8 1.29E+08 1.06E+08  8 7.61E+07 7.98E+07 
IN-p53 7 4.39E+07 4.50E+07  7 5.80E+06 6.81E+06 
wt IN+IN-I-PpoIH78A 2 1.68E+08 9.55E+07  2 9.86E+08 1.18E+09 
wt IN+IN-I-PpoIN119A 3 2.42E+08 2.61E+08  2 4.37E+09 6.02E+09 
IND64V+IN-I-PpoIH78A 2 8.71E+07 5.51E+07  1 1.47E+08   
IND64V+IN-I-PpoIN119A 3 2.05E+08 3.16E+08  3 4.08E+08 6.19E+08 
    TU, transducing unit. 
Figure 10. Characterization of LVVs and VLPs with immunoblotting. Particle-contained IN-molecules 
are identified above the blots and the antibodies used below the blots. The numbers and bars 
indicate locations and sizes of the molecular weight marker bands (kDa). A) Detection of IN proteins 
B) Detection of mCherry and p53. C) Detection of vector-contained RT proteins D) Detecting 
different forms of the Gag-proteins. Asterisks in A and B: correct-sized IN-fusion proteins where 
multiple bands are visible.  Expected sizes of different molecules: wt IN and IND64V, 32 kDa; IN-I-
PpoI/H78A/N119A, 50kDa; IN-mCherry: 59 kDa; IN-p53, 85 kDa; RT proteins, 51 and 66 kDa; Gag-
precursor proteins: p166 (Pr166 Gag-Pol, 166 kDa); p55 (Pr55 Gag, 55 kDa); p41 (an intermediate 
protein, 41 kDa) and the processed p24 (CA, 24 kDa). 
5.1.3 Functional titering and p24 values  
LVVs were characterized by their p24 CA protein content and by functional titers based on the 
expression of the vector-contained GFP transgene. p24 forms the cone-shaped virion capsid, or 
core,  that encloses the viral enzymes and the RNA genome coated by NC (Freed & Martin 
2007). The stoichiometry of p24 generally used for particle amount calculation is 2000 molecules 
per viral particle, but there are also estimates of 1500 copies per particle (Briggs et al. 2004). In 
addition to vector-incorporated CA, the p24 antigen capture enzyme immunoassay used in this 
study measures the amounts of free p24 and p55Gag precursor proteins released into the 
supernatant of producer cells. Therefore it cannot be used to calculate reliably the amount of 
viral particles in a volume. Here the p24 values of LVV and VLP preparations were mainly 
utilized to equalize the amounts of vectors and VLPs being used in various assays.   
Inclusion of the IN-fusion proteins into vectors and VLPs had rather subtle effects on the p24-
contents of vector preparations (Table 12 and Fig. 11 A). The variation seen between different 
lots of the same vector suggest that the differences in the p24-values have likely arisen by 
chance. Although certain IN-fusion proteins, such as the largest IN-p53, may have negatively 
impacted on the vector production, the p24 contents of the IN-modified LVV’s exceeded those 
of the IND64V vectors. In summary, characterization of the IN-modified vectors by their p24-
values suggested that the IN-fusion packaging plasmids can be used for LVV and VLP 
production without markedly altering the levels of particle production. Another conclusion that 
can be drawn is that incorporation of proapoptotic proteins such as the p53 with the cis-
packaging method does not compromise vector production. However, analyzing the p24-values 
of vector preparations with methods that measure only particle-associated CA proteins would 
provide a more reliable basis for such comparisons and conclusions. 
 
Table 12. Mean values and standard deviations (SD) of the particle (p24) and functional titers of 
produced LVVs.  
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In this study, the functional titers, expressed as transducing units per milliliter (TU/ml), of 
LVVs were determined in HeLa cells at a time point between 36 to 48 hours post transduction. 
Transgene expression by LVVs generally reaches its maximum during this time, after which the 
percentage of GFP-expressing cells may decline if non-integrated vector genomes or producer 
cell-originated plasmid DNA have been present in LVV preparations. Therefore the time point 
of functional titer determination does not reflect the integration ability of the vectors.  
Functional titers of the IDLVs (LVV-IND64V) were over two logs lower than those of wt IN 
vectors, being in agreement  with previous studies (Leavitt et al. 1996). The functional titers of 
the IN-fusion protein-containing vectors were 6 to 51 times lower with the IN-I-PpoI proteins 
and 43 to 562 times lower for the IN-mCherry and IN-p53-containing vectors in comparison to 
unmodified LVVs (Fig. 11 B and table 12). Trans-complementation with both IND64V and wt IN 
improved the titers of the LVVs containing different IN-I-PpoI forms. Fusion protein-containing 
LVVs may have altered kinetics with regard to nuclear import of the PIC, integration and 
transgene expression when compared to the non-modified vectors. These differences can affect 
the TU/ml values obtained by flow cytometry analysis, and methods based on integrated 
provirus quantification in transduced cells could provide a more accurate measure of vector 
functionality. FACS-titering was however able to show an unambiguous decrease in vector 
titers that followed the use of IN-fusion protein packaging plasmids in vector production.  
 
Figure 11. Measured p24-contents (A) and functional titers (B) of LVVs and VLPs containing different 
IN-molecules (identified at the bottom of the figure). All of the LVVs carried the GFP-transgene 
construct. SEM, standard error of the mean. 
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5.1.4 Integration proficiency of IN-modified vectors  
The integration proficiency of different LVVs was estimated with flow cytometry. Transduced 
cells were cultivated for at least 10 days to allow dilution of unintegrated vectors, and analyzed 
at regular intervals to determine the percentage of GFP positive cells at different time points. A 
relative integration efficiency value (RIE) was calculated from these measurements by dividing 
the percentage of gated positive cells at a time point by the maximum percentage of positive 
cells obtained for that vector, which was generally observed at day two post transduction. The 
RIE-value thus represents the percentage of cells harboring integrated vectors from all initially 
transgene positive cells, which may have expressed GFP from unintegrated vector genomes.  
The RIE-value of wt IN-containing vectors remained close to 100% throughout the follow-up 
time (Fig. 12 B, D and F). Vectors that contained only the IN-I-PpoIN119A fusion proteins yielded 
identical RIE-curves with the IND64V-containing IDLVs with a RIE value of about 3% at day 10 
(Fig. 12 B). Trans-complementation of LVV-IN-I-PpoIN119A with IND64V resulted in a RIE value of 
33 to 60% depending on the experiment (Fig. 12 B and F). Similar levels of integration 
restoration have been obtained with other published IN-fusion proteins that were used to trans-
complement IDLVs with the Vpr-fusion strategy (Holmes-Son and Chow 2000; Tan et al. 2006). 
Addition of wt IN into IN-I-PpoIN119A-containing LVVs restored the integration efficiency 
close to that of the unmodified vectors (RIE values of 84 and 95%, Fig. 12 B and F, respectively). 
IDLV –driven transgene expression dropped close to the background levels by day 10, but 
expression from integrated vectors remained stable after this time point. Transduction 
experiments were also conducted with LVVs containing the endonucleolytically active IN-I-
PpoI or IN-I-PpoIH78A proteins, but these proteins were found to be cytotoxic in HeLa cells 
(section 5.2.3.2 and Fig. 13).  RIE-value calculations for IN-I-PpoI or IN-I-PpoIH78A containing 
vectors were therefore impeded by the extinction of GFP positive cells before day 10. 
The vectors containing IN-mCherry promoted transgene integration better than the IN-I-
PpoIN119A-containing vectors in the absence of trans-complementation (Fig. 12 B and D). It thus 
seems that the protein fused to IN affects the ability of the vector to integrate to a different 
extent: the monomeric mCherry protein disabled IN’s activities less than the strong 
dimerization-characteristics possessing I-PpoIN119A. However, despite the differences in the 
initial numbers of GFP-expressing cells, surprisingly similar-sized populations of GFP-positive 
cells were found with both LVV-INmCherry concentrations at the end of the study (Fig. 12 C).   
In summary, trans-complementation rescues integration proficiency of IN-fusion protein-
containing vectors and different fusion partners affect the integration capability of IN to a 
different extent. The RIE-calculation used to provide an estimate of the vectors’ integration 
proficiency was found to be affected by differences in transduction conditions and other 
variables between individual experiments, as seen from the values obtained for LVVs wt 
IN/IND64V+IN-I-PpoIN119A (Fig. 12 B and F). If more accurate estimates of integration proficiency 
were needed, the amount of integrated vectors in transduced cells could be determined by 
quantitative PCR (qPCR), which is not sensitive for variation in vector and target cell conditions 
and can also be used for LVV titering (Butler et al. 2001; Gay et al. 2012; Sastry et al. 2002). The 
generation of only wt IN or IND64V–containing vector particles in the trans-complementation 
batches cannot be avoided. The wt IN only-containing particles likely contribute in part to the 
better RIE of such mixed multimer vectors, seen in Fig. 12 B and F. Using IND64V as the 
complementing molecule ensures that the only proteins capable of catalyzing transgene 
integration in the mixed multimer vectors are the IN-fusion proteins.   
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Figure 12. The amount of GFP-expressing transgene positive cells in a population following LVV 
transduction (left) and the relative integration efficiency calculated for different vectors at the 
indicated time points (right). The values are shown as means of replicates ±SD (standard deviation) 
except for A and B, which show averages (Avgs) of two replicates used. TD, transduction 
experiment; RIE, relative integration efficiency; GFP, green fluorescent protein; (+) positive.  
 
5.2 PROTEIN TRANSDUCTION WITH IN-FUSION PROTEINS (I-III) 
Using the cis-packaging method, about 20 to 250 molecules of IN fusion proteins are expected to 
become packaged into vector particles, based on the numbers suggested for IN-molecule 
incorporation into HIV-1 or LVV particles (Briggs et al. 2004; Denard et al. 2009). This number is 
much less than that of trans-packaged Vpr, of which about 390–550 molecules are incorporated 
(Singh et al. 2000). For certain protein transduction applications, it is necessary to transport as 
many molecules as possible into target cells. On other occasions, the target cells may suffer from 
an excess of the delivered proteins. The feasibility of the cis-packaging strategy for protein 
transduction was studied using three IN-fusion proteins with different characteristics and 
potential applications. 
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5.2.1 Apoptosis induction by IN-p53 (I) 
Vpr-fusion proteins have previously failed to promote packaging of a proapoptotic protein into 
lentivirus-derived PTNs (Link et al. 2006). To test whether the cis-packaging strategy presented 
in this work would perform better, an IN-p53 fusion protein was generated and tested for its 
ability to induce apoptosis in p53-sensitive target cells.  
Apoptosis, or the programmed cellular death, is an important pathway that can be induced 
by both extracellular and intracellular stimuli (Taylor et al. 2008). Apoptosis is mediated by 
caspase proteins, the active forms of which increase in cells during the course of apoptosis. The 
tumor suppressor protein p53 is a cellular safeguard that plays critical roles in the maintenance 
of cellular integrity under stress conditions. It can induce apoptosis through its transcription 
factor-related functions or via transcription-independent pathways by directly localizing to the 
mitochondria (Green and Kroemer 2009). The p53 gene is inactivated through mutations or 
deletions in approximately half of different types of human cancers. In the cervical carcinoma 
HeLa cells used in this work to study the activity of IN-p53 protein transduction, the 
endogenous p53 protein is targeted for accelerated degradation through the action of the 
human papilloma virus (HPV) E6 protein (Scheffner et al. 1993; Scheffner et al. 1990).  
Induction of apoptosis in HeLa cells was studied by using different LVV and VLP amounts 
in transductions, and by measuring the intracellular amounts of the active effector caspases 3 
and 7 at different time points post transduction. Caspase 3 and 7 signals were found to be 
significantly elevated in cells transduced with the LVVs or VLPs containing the IN-p53 protein 
when compared to cells treated with the wt IN-containing control vectors (original publication 
I, Fig. 4). This result confirmed that protein transduction with either LVV of VLPs was able to 
induce apoptosis in HeLa cells. Moreover, the result demonstrated that IN-fusion proteins can 
be used to package proapoptotic proteins into lentivirus-derived particles and that these 
particles can elicit the anticipated response in the target cells.  
5.2.2 Fluorescent labeling of LVVs and VLPs by IN-mCherry (I) 
Different proteins of LVs and γRVs have been tagged with fluorescent proteins to track the 
intracellular trafficking of viral particles (reviewed in Maetzig et al. 2012). A fusion protein 
consisting of IN and the monomeric red fluorescent protein mCherry (Shaner et al. 2004) was 
generated in this study to test whether LVV or VLP-packaged IN-fusion proteins could be used 
for the same purpose. Imaging IN-mCherry containing particles with confocal microscopy 
verified that the fluorescent fusion protein was correctly and specifically packaged into both 
LVVs and VLPs (original publication I, Fig. 7). Despite the lower number of IN molecules in 
virions in comparison to e.g. Vpr, the amount of the cis-packaged proteins sufficed for the 
microscopical visualization of the generated particles. Moreover, red fluorescing particles were 
detected in the cytoplasm and nuclei of LVV-IN-mCherry -transduced cells, confirming the 
feasibility of using IN-fusion proteins for intracellular trafficking studies of LVVs and VLPs. 
5.2.3 Endonuclease protein transduction (II, III) 
As discussed before, the generation of DSBs can be advantageous in gene therapy, owing to 
their ability to enhance site-specific gene insertion into the cleaved site (Urnov et al. 2010). 
High-level expression of nucleases in target cells can, however, lead to unspecific genome 
cleavage and the related genotoxicity. Nuclease expression can be bypassed by providing the 
enzyme through lentiviral protein transduction (Izmiryan et al. 2011), which per se does not 
elicit cytotoxicity. However, the nature of the endonuclease used, the amount of molecules 
packaged into PTNs and the number of target sites at which it causes cleavage can affect the 
cytotoxicity encountered with this approach.  
In addition to integration targeting studies, LVVs and VLPs carrying the endonucleolytically 
active forms of the IN-I-PpoI fusion (see 5.1) were used to characterize the suitability of the cis-
packaging approach for endonuclease protein transduction. This was done by testing the DNA-
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cleaving activity of the IN-fusion proteins on both plasmid DNA and in transduced cells and by 
measuring their cytotoxicity in different human cells and in an in vivo tumour model.   
5.2.3.1 IN-I-PpoI is functional both in vitro and in transduced cells 
In this study, the functionality of IN-fused I-PpoI was tested in a plasmid cleavage assay with 
two methods, first with recombinant proteins (original publication II, Supplementary Fig. 1) 
and next with a newly developed strategy using LVV or VLP-extracted proteins (original 
publication III, Supplementary Fig. S1). Plasmids containing I-PpoI recognition sites were 
efficiently digested by IN-I-PpoI and IN-I-PpoIH78A, but not with wt IN. Both of the I-PpoI 
variants were thus confirmed to remain active despite their fusion to IN.  
Accessibility of the genomic rDNA-target site for lentivirally delivered IN-I-PpoI and its 
correct cleavage was studied using immunocytochemistry and confocal microscopy. The 
histone H2AX becomes phosphorylated at a serine residue in response to DSBs and forms so-
called γH2AX foci that span large chromatin areas (Rogakou et al. 1998). In addition, the 
obligatory target DNA cleavage step of retroviral integration involves H2AX phosphorylation 
(Daniel et al. 2004), and this property allows for detection of early integration events through 
γH2AX staining. 
Clear evidence of DSB signal concentration around the nucleoli was observed in cells 
transduced with the endonucleolytically active fusion proteins IN-I-PpoI (original publication 
II, Fig. 3 and Supplementary Fig. 2) and IN-I-PpoIH78A (original publication III, Supplementary 
Fig. S1). Single γH2AX foci were visible also outside the nucleoli, indicating either integration 
reactions occurring elsewhere in the genome or IN-I-PpoI activity on some of its non-nucleolar 
target sites (table 13). As vectors containing solely the IN-I-PpoIN119A fusion protein were found 
to be severely compromised for integration in the RIE-study (Fig. 12 B), the latter explanation is 
more likely. γH2AX foci were not found to surround the nucleoli of cells transduced with 
vectors or VLPs that lacked the I-PpoI endonuclease activity, i.e. with particles containing IN-I-
PpoIN119A and wt IN. In addition, the nucleolar morphologies were distinct in these cells when 
compared to the ring-like structures observed in IN-I-PpoI and IN-I-PpoIH78A transduced cells 
(original publications II and III, Figures 3 and S1, respectively). Taken together, these tests 
indicated that I-PpoI and I-PpoIH78A proteins are able to correctly recognize and cleave the I-
PpoI target sites present on both plasmids and genomic DNA, when fused to HIV-1 IN. 
   
Table 13. Full 15 bp I-PpoI cleavage sites (CTCTCTTAAGGTAGC) in the non-ribosomal genomic DNA 
(GRCh37.p5; original publication II).  
 
 
 
 
 
 
 
 
 
 
 
 
5.2.3.2 The impact of IN-I-PpoI protein transduction on cellular viability  
When site-specific endonucleases are transduced into cells with the aim of genome editing or 
targeted integration, the number of transported molecules needs to be sufficient to obtain 
efficient target site cleavage but low enough to avoid unintended genotoxicity. IN molecules are 
packaged into vector particles at much lower numbers than Vpr-fusion proteins, making the cis-
start end 
Chromosome  
and cytoband 
Orientation 
28425200 28425214 1p32.2 - 
31284197 31284211 1q43 + 
22786092 22786106 2q21.2 - 
56304065 56304079 3p14.3 - 
6560338 6560352 7q11.22 + 
22466898 22466912 8q13.3 - 
22903380 22903394 11q14.1 + 
31593767 31593781 Xq22.3 + 
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packaging method potentially well-suited for endonuclease protein transduction. To test this 
hypothesis, the cytotoxicity of IN-I-PpoI transduction was assessed in different cells.  
The tested cell lines included both non-transformed and finitely dividing cells (Table 4). The 
cancer predisposition frequently involves mutations in the pathways that ensure genomic 
stability after DNA damage, which renders these cells more sensitive for radiotherapy or DSB-
originated cytotoxicity (Khanna and Jackson 2001). The differences in viabilities between 
cancerous and normal cells were therefore evaluated. Indeed, the present studies suggested that 
the cells suffering most from IN-I-PpoI protein transduction were cancer cells, or cells with 
dysfunctional responses to DNA damage, such as the 293T cells (Fleisig et al. 2010) (original 
publication III, Fig. 4 and Supplementary Figs. S3 and S4).  However, there was much variation 
in how different cell lines responded to IN-I-PpoI protein transduction. Whereas some cell lines, 
such as the A549 lung carcinoma cells, showed a clear and dose-responsive reduction in 
viability following LVV IN-I-PpoI transduction, other cancer cell lines, e.g. the HepG2, seemed 
to become affected at later time points and were less vulnerable to vector-derived DSBs even 
after the highest vector loads used (original publication III, Supplementary Fig. S4). The 
cytotoxic effects of IN-I-PpoI were not restricted to cancer cells, but were also evident in some of 
the non-cancerous cells, such as normal retinal pigment epithelium ARPE-19 cells. I-PpoI has 
about 600 natural cleavage sites in the human genome, including the ones in rDNA and in the 
non-nucleolar chromosomes (Table 13). Despite the limited cleavage of genomic I-PpoI sites by 
the enzyme (Monnat et al. 1999; Berkovich et al. 2007; Gandhi et al. 2012; Wen et al. 2012), its 
activity therefore poses a major challenge also for cells possessing normal DSBR pathways. 
The more pronounced cytotoxicity of IN-I-PpoI transduction in cancer cells was taken 
advantage of in order to characterize the functionality of lentiviral IN-endonuclease protein 
transduction in a more complex environment, in an in vivo setting. The lung carcinoma A549 
cells, which had been verified to be susceptible for I-PpoI site cleavage-originated cytotoxicity 
in in vitro tests, were used to generate subcutaneous tumors in the backs of nude mice. Tumors 
were injected with the inert GFP transgene-containing wt IN control vectors, with LVV-IN-I-
PpoI and with a control vector carrying the HSV TK transgene. LVV-IN-I-PpoI transduction 
was found to decrease the proliferation of tumor cells with a similar or better efficiency as 
observed for the LVV-wt IN-TK vector combined with GCV treatment. Taken together, IN-I-
PpoI protein transduction elicited efficient tumor cell cytotoxicity not only in cultured cells but 
also in an in vivo setting, verifying the feasibility of the cis-packaging method for LVV-driven 
protein transduction in two different study environments. With moderate LVV doses, the extent 
of DNA cleavage did not cause overt cytotoxicity in non-cancerous cells. 
5.2.3.3 Decreasing endonuclease-derived cytotoxicity by trans-complementation  
After demonstrating the feasibility of cytotoxic IN-endonuclease protein transduction in 
different cells and transduction environments, it was decided to examine whether the IN-I-
PpoIH78A mutant combined with a described 52% decrease in endonuclease activity (Mannino et 
al. 1999) would have a smaller impact on the viability of the transduced cells than IN-I-PpoI. 
Moreover, mixed multimer vectors were used to test whether intravirion endonuclease levels 
could be reduced to a less cytotoxic level by trans-complementation. The two concentrations of 
vectors used (2 and 10 ng of p24 per well of a 96 well plate) corresponded to approximately to 
2000 and 12500 viral particles per cell, respectively. 
The vector loads used in the study were not cytotoxic on the cells per se, as evidenced by the 
endonuclease activity-lacking vectors containing LVV-wt IN and LVV-IN-I-PpoIN119A (Fig. 13 A-
D). LVV-IN-I-PpoIH78A was found to be less cytotoxic in both cell lines at the lower dose than the 
fully active IN-I-PpoI enzyme (Fig. 13 E and F). IN-endonuclease protein transduction was 
again observed to be more toxic in the cancerous HeLa cells than in the normal MRC-5 
fibroblasts (Fig. 13 E-H). By adding IND64V or wt IN into LVVs containing the IN-I-PpoIH78A 
endonuclease, the cytotoxicity of vectors could be further reduced (Fig. 13 G and H). The trans-
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complementation approach was thus found to be a feasible way to decrease the endonuclease 
content inside LVV particles to reduce DSB-originated cytotoxicity.  
 
 
Figure 13. The impact of different vector-contained IN-proteins on cellular viability. Significant 
negative deviation (decreased viability) from the values of non-transduced cells are shown with 
black asterisks, and significant differences between the two cell lines at day 3 with grey asterisks. 
Statistical calculations were performed with one-way Anova followed by Dunnett’s multiple 
comparison tests. LVVs containing wt IN and IN-I-PpoIN119A were used as the no endonuclease 
activity-containing controls. P-value summary: *: 0,01<p<0.05; **: 0.01<p<0.001; ***: p<0.001. 
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5.3 TARGETING A GENOMIC SAFE HARBOR FOR TRANSGENE 
INTEGRATION (II) 
The main goal of this study was to test whether IN-fusion proteins could be used to increase 
vector integration at a predetermined site when packaged into third generation LVVs. To test 
this hypothesis, HIV-1 IN was fused to I-PpoI that has many natural recognition sites in an 
interesting GSH candidate, the rDNA. In addition to characterizing the frequency of targeted 
transgene integration events, the full integromes of the vectors were analyzed. The rationale 
behind this was that comprehensive characterization of a vector’s off-target integration events is 
highly important as it aids in the assessment of the vector’s genosafety profile. In addition, the 
incorporation of an IN-fusion protein into vectors may affect the interaction of IN with its 
cellular cofactors and lead to a change in the vector’s integration pattern.  
5.3.1 Integration site study data sets  
Vector ISs in cellular genomes were analysed by LM-PCR followed by pyrosequencing, as 
described  in the original publication II. The different vectors studied are listed in Table 14. Data 
sets with less than 100 ISs were not included in further IS analysis steps due to the high 
likelihood of chance affecting the results. In this thesis, the unpublished data generated with 
LVVs wt IN and wt IN+IN-I-PpoIH78A are included in cellular integration site analysis. LVV wt 
IN is included as an internal control despite the sparse number of ISs in the data. The largest 
numbers of ISs were obtained with the best integration proficiency and least cytotoxicity 
demonstrating IN-fusion protein vectors, namely LVVs wt IN+IN-I-PpoIN119A and IND64V+IN-I-
PpoIN119A (table 14). LVV wt IN+IN-I-PpoIH78A was the only endonuclease activity possessing an 
IN-fusion protein vector for which a reasonable number of cellular ISs could be resolved.  
The results obtained for IN-modified vectors were compared to external published HIV-1 
integration data sets (hereafter referred to as the control vector or data) to ensure that the 
comparisons be as accurate as possible. The data set published by Mitchell et al. (2004) was 
chosen because it was generated with the same REs and extracted from a similar cell line 
(IMR90 normal lung fibroblast) as the IS data in this work, and should therefore contain an 
identical inherent restriction bias. A larger external wt IN-data set was necessary to use in 
rDNA-targeting studies (Wang et al. 2007). Each data set was additionally compared to their 
MRC data (see later). During bioinformatics filtering of obtained sequencing reads, a match to 
the genomic DNA was required to start latest two nucleotides after the processed LTR end. 
Final integration site data sets therefore present IN-catalyzed integration events.  
 
Table 14. Vectors used in genomic IS studies and the number of final ISs in the genome version 
hg18/NCBI Build 36.1 (released date Mar. 2006). ND, not determined; U.P., unpublished results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LVV type LVV name Described in  # of IS 
Control vectors LVV wt IN  This thesis, U.P. 103 
LVV IND64V This thesis, U.P. 37 
Vectors with only  
IN-fusion 
proteins  
LVV IN-I-PpoI ND ND 
LVV IN-I-PpoIH78A This thesis, U.P. 7 
LVV IN-I-PpoIN119A ND ND 
Mixed multimer 
vectors 
LVV IND64V + IN-I-PpoIH78A This thesis, U.P. 58 
LVV wt IN + IN-I-PpoIH78A     This thesis, U.P. 254 
LVV IND64V + IN-I-PpoIN119A  This thesis (II) 437 
LVV wt IN + IN-I-PpoIN119A  This thesis (II) 1609 
  
External controls  LVV wt IN  Mitchell et al., 2004 480 
LVV wt IN  Wang et al., 2007 40 604 
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5.3.2 Targeted integration into ribosomal DNA 
rDNA is absent from the so-called complete sequenced human genome builds, because the 
sequencing of individual rRNA gene repeats and their mapping into correct rDNA-containing 
chromosomes is impossible with the currently available strategies (International Human 
Genome Sequencing Consortium* 2004). However, in the unannoted genome build versions 
hg19/GRCh37, unplaced contigs containing rRNA genes can be found. The supercontig 
ChrUn_gl000220 was analyzed in this work to contain one full and one partial rRNA gene 
repeat, with a complete intervening IGS sequence and areas to which no rRNA-related genes 
could be mapped to (Figure 14). Analysis of IS localization to the rDNA was conducted by 
BLAT-aligning sequence reads to hg19 and by counting unique hits in the ChrUn_gl000220. 
No rDNA-localizing ISs were found in the smaller external wt IN control data set, nor in data 
sets generated in this work that contained the fewest integration sites (254 sites or less). The 
background level of LVV integration within rDNA was therefore determined using the larger 
data set published by Wang et al. (2007). Altogether 0.1% of the vector’s integration sites were 
found in rDNA, scattered throughout the length of the unplaced contig (Fig. 14 and 15). In 
contrast, ISs were found solely within the 18S and 28S rRNA genes for the IN-fusion protein-
containing vectors. LVV-IND64V+IN-I-PpoIN119A, which had a comparable number of ISs with the 
smaller wt IN control (Mitchell et al., 2004), featured best integration targeting to rDNA (2.7% of 
all genomic ISs), the difference to all other vector groups of relevant size being significant 
(Figure 15).  This result answered the main study question of this work, confirming that IN-
fusion proteins can be used to increase vector integration at a predetermined GSH site. The 
reason behind the lesser degree of rDNA targeting by the wt IN-complemented IN-I-PpoIN119A 
vectors is likely due to the presence of only-wt IN-containing particles in the vector preparation, 
which integrate more randomly than true mixed-multimer vectors.  
 
Figure 14. A schematic of the unplaced supercontig ChrUn_gl000220 (modified from original 
publication II).  The GC-percentage, CpG islands and rRNA gene sequences are shown in addition to 
vector integration sites (bottom of the figure). 
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Figure 15. Percentage of vector ISs in rDNA. The p-values shown arise from comparisons between 
LVV IND64V+IN-I-PpoIN119A and the rest of the vectors (Fisher’s exact test and X2-test when 
comparing to the wt IN control from Wang et al. 2007). 
5.3.3 The overall integration pattern of IN-I-PpoI-containing LVVs 
HIV-1 prefers integration within actively transcribed genes and disfavors certain genomic 
features favored by γRVs, such as TSSs (Beard et al. 2007a; Berry et al. 2006; Wang et al. 2007). 
Owing partly to the differences in IS selection by the two Retrovirus families, LVVs are less 
genotoxic than γRVVs (Montini et al. 2009). In order to test whether IN-fusion protein-
containing vectors would retain the favorable integration pattern of LVs, their overall genomic 
IS distribution was studied. Sites localizing to different genomic features were analyzed using 
the software InSiPiD (INtegration SIte PIpeline & Database; 
http://microb215.med.upenn.edu/insipid/index.php) of the Bushman laboratory (Berry et al. 
2006). For each data set created here, it generated a unique MRC data set in which three 
computationally selected random ISs lie the same distance to an RE site as the corresponding IS 
for an LVV, but are otherwise randomly distributed (Berry et al. 2006; Mitchell et al. 2004; see 
also section 2.2.3).  
The results are illustrated as a genomic heat map (Fig. 16), which summarizes integration 
profiles of vectors or viruses with regard to their different genomic features (listed to the left). 
Each vector data set studied was compared to its own MRC (asterisks in Fig. 16), the best 
control featuring random integration. The tile color represents the nature of differences between 
vector ISs and MRC sites: increasing shades of red indicate more integration sites in the given 
feature, and increasing shades of blue indicate disfavored integration in the feature, as 
compared to random integration. The wt IN control generated in this work was shown in the 
heat map to verify its similarity with the external control data. Owing to the low IS numbers 
obtained, this data was not analyzed in detail.  
In an attempt to resolve possible differences to the integration preference of a typical LVV, 
the IS distribution of IN-modified vectors was compared to that of the same restriction bias-
containing wt IN control data (Mitchell et al. 2004; triangles in Fig. 16). No significant 
differences were present between the internal and the external control LVVs, verifying the 
reliability of the method used for IS extraction. Several differences were observed when 
comparing the integration pattern of the IN-fusion protein containing LVVs and the control, 
and the most relevant of these will be discussed in more detail below. 
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Figure 16. Integration frequency in different genomic features. A genomic heat map summarizing 
the relationships of vector integration sites with their MRC data and comparing the integration 
pattern of IN-modified vectors to the control vector data is shown. Data set names are indicated 
above the columns. Selected genomic features are designated to the left of the corresponding row of 
the heat map. Tile color indicates whether integration by different vectors is favored (increasing 
shades of red) or disfavored (increasing shades of blue) in a given feature relative to their MRCs. 
The p-values shown (*p<0.05, **p<0.01, ***p<0.001) emerge from significant departures from 
the MRCs (asterisks) or from the wt IN data set (triangles). The base pair values in the row labels 
indicate the size of the genomic interval used for analysis. The statistical methods used in the 
InSiPiD-generated heat map to compare experimental data sets to their MRCs and to each other are 
described elsewhere (Berry et al. 2006; Brady et al. 2009). 
5.3.3.1 Integration with respect to genes and oncogenes 
HIV-1 has a strong preference towards integration within transcription units (Wang et al. 2007). 
RefSeqGenes (RSGs) is a subset of NCBI's Reference Sequence project that serves as a reference 
standard for well-characterized genes. All of the studied vectors preferred integration into RSGs 
when compared to random (Fig. 16). LVV wt IN+IN-I-PpoIN119A had more (73.5%) and LVV wt 
IN+IN-I-PpoIH78A fewer (64.8%) ISs within RSGs than the control vector in this comparison 
(69.8%) (Figure 16 B and table 14). Typical gene-targeting frequencies of HIV-1 vectors do, 
however, often reach values of more than 70%. 
Within genes, IN-I-PpoIN119A-containing vectors were found more frequently in exons than 
would be expected by chance (Table 15; all LVV data sets compared to their respective MRCs). 
Control vectors or the other IN-modified vectors studied showed no such preference, and the 
overall frequency of targeting an exon remained below 6% in all listed data sets.  
LVV wt IN+IN-I-PpoIN119A differed significantly from the external wt IN control in preferring 
more gene-dense regions for integration (Fig. 16). This difference was, however, only visible at 
the largest 1Mb window studied, and may arise from the fact these vectors had almost double 
the amount of IS in the gene-densest chromosome 19 in comparison to the control vectors (Fig. 
17). With regard to all other measures describing integration with respect to genes, including 
gene density and distance to nearest start site, IN-modified vectors and the control did not 
significantly differ from each other (Fig. 16). 
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HIV-1 integrates into oncogenes more frequently than would be expected by chance (Beard 
et al. 2007a; Brady et al. 2009). In this analysis, only the control vector and the LVV wt IN+IN-I-
PpoIN119A repeated this tendency when looking at a 50 kb region around ISs (Fig. 16). When 
analyzing IS localizing directly within oncogenes, all of the IN-modified vectors did, however, 
duplicate this lentiviral preference (Table 15). The differences between the IN-fusion protein 
vectors and the wt IN data used as an external control were not significant (two-sided Fisher’s 
exact test). 
Taken together, the above described results suggest that the IN-modified vectors retain the 
typical characteristics of LVVs with respect to integration into or close to genes and oncogenes. 
Small differences are found between the control vector and the wt IN+IN-I-PpoIN119A-containing 
LVVs when looking at favored intragenic insertion sites and gene dense regions. Such variation 
may however result from the different number of analyzed IS per vectors. 
 
Table 15. LVV and MRC sites localizing into genes, oncogenes and CpG islands, and the GC 
percentage at 20bp around the IS.  
 
5.3.3.2 CpG islands, GC-rich DNA and DNase hypersensitive sites 
As previously described, LV integration is favored in large genomic areas with a high CpG 
frequency, correlating with their tendency to integrate into areas rich in active genes (Berry et 
al. 2006; Wang et al. 2007; Brady et al. 2009). CpG islands are, however, not enriched directly 
around the ISs, reflecting LV’s preference towards genes instead of promoters or TSSs, which 
typically contain CpG islands.  
In this study, the ISs of IN-I-PpoIN119A-containing vectors were found more frequently in 
CpG-rich DNA, than observed for the control vector (Fig. 16). The differences between both of 
these IN-modified vectors in comparison to the control LVV were significant, albeit small, at the 
smallest 1kb window studied (Fig. 16 and Table 15). This characteristic may be implicative of an 
increased integration favoring towards promoter areas, which is relevant for assessing the 
genotoxic potential of the vectors. 
The LV tendency of favoring large genomic GC-rich areas for integration was replicated in all 
of the IN-fusion protein-containing LVVs (Fig. 16). At smaller window sizes, the GC preference 
was, however, not switched to the expected AT preference, which was visible in the wt IN 
control data set. In contrast, IN-fusion protein-containing vectors continued to favor GC-rich 
sequences close to the site of integration (Table 15). One explanation for the change could be an 
altered interaction with the IS-determining cellular co-factor of IN, the LEDGF/p75, which 
contains an AT hook which is thought to tether IN to AT-rich DNA (Ciuffi et al. 2005).  
Vector / MRC name Described in
# of 
ISs
In RSG
In RSG
exon
In 
allOncob
CpG 
<1 kb
GC% 
20bp
wt IN+IN-I-PpoIN119A This thesis (II) 1609 73.5*** 5.8*** 9.4*** 2.5 46.5***
IND64V+IN-I-PpoIN119A This thesis (II) 437 69.8*** 5.3*** 9.0** 4.4** 44.8***
wt IN+IN-I-PpoIH78A This thesis, U.P. 254 63.8*** 2.4 9.1*** 0.4 47.7***
wt IN This thesis, U.P. 103 68.9*** 3.9 6.8 0.0 45.2
wt IN Mitchell et al., 2004 480 69.8*** 3.3 8.3*** 0.4 39.8
wt IN+IN-I-PpoIN119A This thesis (II) 4827 40.6 1.9 4.7 1.7 41.0
IND64V+IN-I-PpoIN119A This thesis (II) 1311 41.3 2.0 4.9 1.8 41.1
wt IN+IN-I-PpoIH78A This thesis, U.P. 671 37.9 2.5 3.3 1.3 41.0
wt IN (this work) This thesis, U.P. 309 39.8 2.3 3.6 1.9 42.0
wt IN Mitchell et al., 2004 6237 39.1 2.0 4.1 1.4 41.0
RSG: RefSeq. Gene; MRC, Matched random controls     
 bhttp://microb230.med.upenn.edu/protocols/cancergenes.html.
Vectors
MRCs
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Similar to CpG islands, HIV ISs positively correlate with a high DNase hypersensitive site 
content when analyzed over long intervals (Brady et al. 2009). In this respect, the IN-modified 
LVVs did not significantly differ from the control, except for the LVV wt IN+IN-I-PpoIH78A at the 
largest window size of 1Mb (Fig. 16). Since this difference was restricted to a long distance, this 
modified vector did not preferentially integrate near to promoter areas, which are enriched with 
DNase hypersensitive sites.  
Taken together, studying vector ISs with respect to different genomic features associated 
with gene-dense chromatin and gene regulatory areas revealed that IN-I-PpoIN119A-containing 
vectors tended to integrate into CpG islands more often than the control. Since their ISs were 
not found to differ from those of the control vector in any other sites studied which would be 
indicative of promoter areas (e.g. distance to gene start areas and DNase hypersensitive sites), 
this difference must be attributable to some other factors underlying the characteristics of vector 
integration. From the distribution of ISs into chromosomes (Fig. 17), it can be seen that IN-I-
PpoIN119A-containing LVVs integrate more in the gene-densest chromosomes 16,17 and 19, when 
compared to the wt IN control. In addition to high gene density, these chromosomes indeed 
have a particularly high CpG island content (Lander et al. 2001), which can explain this 
observation. However, the overall tendency to target genes for integration did not consistently 
differ between the control vector and the IN-fusion protein LVVs (Fig. 16). Therefore this 
analysis did not reveal any differences in the genotoxicity of vector integration between the IN-
modified and the control vectors, but it did demonstrate a clear local change on the typical LV 
pattern of favoring AT-rich sequences for integration.  
 
 
Figure 17. The chromosomal distribution of ISs. The percentages of LVV ISs per chromosome in the 
human genome are shown. MRCs represents the average of all vectors’ MRC sites. 
 
5.4 INTERACTION OF DIFFERENT I-PPOI FORMS WITH GENOMIC I-PPOI 
RECOGNITION SITES (III) 
Vector IS studies revealed a significant increase in rDNA-directed integration only for the LVV 
containing a mixture of IND64V and IN-I-PpoIN119A (Fig. 15). The ability of the endonuclease 
activity-possessing IN-fusions (IN-I-PpoI and IN-I-PpoIH78A) to recognize and process the 15 bp 
target site was proven by the DNA cleavage experiments both with plasmid DNA and in 
cultured cells. For these vectors, the protein-DNA interaction sites localizing to the non-
nucleolar I-PpoI sites and rDNA were studied as part of the characterization of the cytotoxicity 
of the protein and the functionality of protein transduction (original publication III). Here, also 
the interaction of the non-DNA cleaving IN-I-PpoIN119A proteins is shown.  
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Protein-DNA interaction sites were studied with chromosome immunoprecipitation (ChIP) 
followed by sequencing.  Interactions localizing to rDNA were counted in the Hg19 genome as 
described for IS targeting studies (5.3.2), and co-localization with the non-nucleolar I-PpoI sites 
was also studied. The results revealed enrichment of rDNA-localized interactions for many of 
the vectors containing different forms of I-PpoI proteins (Table 16). The clearest interactions 
were seen for the fusion proteins containing endonuclease activity. With both IN-I-PpoI mutant 
forms, LVVs that were trans-complemented with wt IN had a larger proportion of interaction 
sites localizing to the rDNA/ I-PpoI sites, in comparison to the IND64V trans-complemented 
LVVs. Moreover, IN-I-PpoIN119A was inferior to IN-I-PpoIH78A in interacting with either of the 
targets with I-PpoI recognition sites (Table 16).  
When interpreting the results, it needs to be kept in mind that the method is bound to 
detecting interaction “moments” rather than describing a sum of all interactions occurring at a 
defined site. The differences between vector data sets may thus partly arise by chance and from 
slight differences in the timing of sample preparation. Another possibility is that there can be 
different kinetics in target DNA binding and release between the different IN-I-PpoI forms. For 
example, it could be that the DNA cleavage-deficient fusion proteins dissociate from target 
DNA faster than the proteins that are capable of target DNA cleavage. It is surprising that the 
wt IN-complemented LVVs exhibited a greater interaction with the I-PpoI targets than the 
IND64V-complemented vectors because this result is in conflict with the obtained IS data.  
Qualitative differences possibly occurring also between these two vector types may partly 
explain the discrepancy, e.g. slower nuclear localization kinetics for the IND64V-complemented 
LVVs could have an impact on the ChIP sequencing study results.  
In summary, the ChIP sequencing studies confirmed the ability of all the IN-I-PpoI fusion 
proteins to interact with the rDNA-localized and the non-nucleolar I-PpoI sites, although the 
majority of resolved interaction sites localized elsewhere in the genome. The DNA-binding 
properties of IN-fusion proteins are likely to be dependent on the characteristics of the fusion 
partner. The results obtained in this thesis nevertheless demonstrate that one can induce 
specific protein-DNA interactions through the cis-packaging method.   
 
 
Table 16. Interaction of different IN-fusion proteins with rDNA (ChrUn_gl000220) and the non-rDNA-
localized I-PpoI sites.   
 
n, number of final unique interaction sites found in the genome version Hg19. 
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6 Discussion and future directions  
6.1 IN-FUSION PROTEINS AS A METHOD FOR PROTEIN TRANSDUCTION 
The results obtained in this work support the concept that IN-fusion proteins can be used as 
virion tethers to promote the delivery of foreign proteins into target cells via transduction. The 
advantages of LVVs as protein transduction tools include their efficient entry into a variety of 
cells and the possibility to pseudotype vectors to obtain desired target cell specificity (Cronin et 
al. 2005). IN proteins are packaged into vectors at lower amounts than Vpr fusion proteins. This 
can be advantageous for the delivery of nucleases, which are often toxic if present at high 
concentrations. With cis-packaging, also the negative impacts of Vpr (Zhao et al. 2011) on 
cellular viability can be avoided. 
 In the light of the results obtained in this work, one can state that cis-packaging achieves 
sufficient levels of protein incorporation to make it suitable for different types of applications. 
HIV-1 PR cleavage sites have been introduced into different Vpr fusion proteins to permit the 
dissociation of the trans-packaged protein from its carrier inside virions (Izmiryan et al. 2011; 
Holmes-Son & Chow 2000). Adding such a moiety between the IN and the fusion partner could 
be beneficial in situations where the fusion partner loses activity due to N-terminal fusions. In 
addition, the presence of potential PR cleavage sites could be monitored to minimize the 
possibility for unwanted fusion protein proteolysis. 
The largest fusion partner tested with IN in this work was the tumour suppressor p53. LV 
particles seem to display surprising plasticity with regard to the protein content packaged 
inside the envelope, as duplicate cones can be found in as much as one third of LV particles 
(Briggs et al. 2003). Therefore, packaging much larger proteins, such as TALENs into LVV 
particles could in theory be possible. These proteins have proven to be unsuitable for expression 
from LVVs but not from adenoviral vectors (Holkers et al. 2012). Protein transduction of 
TALENs with LVVs could be an attractive option due to the lower immunogenic nature of 
LVVs in comparison to e.g. adenoviral vectors. The mixed multimer vectors generated in the 
current work showed that two types of proteins can be packaged into the same vector particle, 
which is relevant when considering the delivery of two half-site recognizing nucleases into 
target cells within a single particle.  
One of the advantages of LVVs is that they can transduce complex transgene sequences 
including multicistronic cassettes and non-coding RNAs (reviewed in Schambach et al. 2013). 
Therefore it could be possible to use the cis-packaging method also for the cellular delivery of 
the recent CRISPR-systems, whose advantages include targeting new DNA sequences through 
complementary RNA molecules instead of the more laborious generation of new proteins for 
each target site (Van der Oost 2013). The upper size limit of cis-protein packaging was not tested 
in the present work. Further tests will also be needed in order to characterize the exact impact of 
IN-fusion protein incorporation on the formation of LVV and VLP particles.  
6.1.1 Nuclease cis-packaging and cytotoxicity  
IDLVs have proven their utility in many areas of gene therapy, including ZFN delivery to 
obtain site-specific gene integration (Gabriel et al. 2011; Lombardo et al. 2011; Lombardo et al. 
2007). The most optimal delivery system for ZFNs or other nucleases would be able to promote 
transduction of all of the necessary reaction components within one vector particle, 
concomitantly minimizing the cytotoxic effects of nuclease expression in the target cells. The cis-
protein transduction method used in this study delivered functional I-PpoI meganuclease 
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proteins and expressed transgenes into target cells nuclei, but only few stable transgene-
positive HeLa cells were obtained due to DSB-originated cytotoxicity.  
I-PpoI has approximately 600 target sites in the human genome, including its non-ribosomal 
sites and the ones embedded in the rRNA genes. Transduction of the protein into cells thus 
represents a major challenge for the cellular DNA repair machinery, and the maintenance of 
genomic stability with concurrent DSBs at different chromosomes requires efficient DSBR 
activity. Interestingly, all of the human cell studies where I-PpoI has been involved, and 
subsequently its cytotoxicity has been reported, have been conducted either in transformed cell 
lines or in cells that lack protein functions important in DSB signaling and repair pathways 
(Monnat et al. 1999; Berkovich et al. 2007; Wen et al. 2012). Cells lacking functional DSBRs are 
naturally more vulnerable to DSB-derived cytotoxicity because the unrepaired free DNA ends 
hamper replication and affect genomic stability. Instead of cancer cells, the more likely targets 
for therapeutic gene integration or genome editing are normal primary cells, such as those from 
the hematopoietic origin, or inducible pluripotent stem cells (Takahashi et al. 2007). However, it 
was thought that by examining the cytotoxic impact of I-PpoI target site cleavage in different 
cell types, it could be possible to obtain generic information about this process, and possibly 
also gain new knowledge regarding the feasibility of targeted integration into rDNA through 
DSB induction. Therefore, the cytotoxicity of IN-I-PpoI transduction was examined in non-
transformed and cancerous cell lines. Cytotoxicity was not exclusively restricted, but it was 
more prominent in cancer cell lines in comparison to finitely growing cells possessing no 
known DSBR mutations. The extent of cell death observed in some cancer cells after IN-I-PpoI 
delivery seemed unexpectedly high when considering that I-PpoI should catalyze the formation 
of about  60-180 DSBs per cell [10-30% of its about 600 target sites (Monnat et al. 1999; Gandhi et 
al. 2012; Wen et al. 2012)]. In comparison, about 50 endogenous DSBs per cell are produced in 
every cell cycle (Vilenchik and Knudson 2003), and other forms of nucleotide damage extend to 
levels of 20 000 to 200 000 per cell (Coates et al. 2005). The higher vulnerability of cancer cells to 
rDNA-targeted genome cleavage could arise from their lower genomic stability and from the 
fact that rDNA cluster reorganization is frequently found in these cells (Stults et al. 2009). It is 
also possible that cell type-specific differences exist in the activity of protein ubiquination 
pathways, which could lead to a longer retention of the active enzyme in cancer cell’s nuclei 
where it would be able to recleave potentially already repaired loci. Indeed this has been 
suggested to occur previously (Berkovich et al. 2007).  
Whatever the underlying reasons of I-PpoI cytotoxicity in cancer cells are, the results 
obtained in the present work showed that IN-fusion proteins are suitable for the nuclear 
delivery of a meganuclease. The cytotoxic impact of IN-nuclease delivery is likely to depend on 
the individual characteristics of the target cells, the amount of endonuclease delivered and the 
activity and genomic cleavage site numbers of the specific endonuclease in question. Future 
studies combining more specific endonuclease, such as ZFNs, with the IN-fusion protein 
delivery strategy could shed light on the true utility of the developed method in the field of 
gene therapy, for example for HR-induced targeted gene addition/genome editing, or for the 
directed disruption of sequences by NHEJ. Moreover, a strictly rDNA-specific nuclease would 
be useful in determining the safety of rDNA cleavage in clinically relevant cell types, such as 
those from the hematopoietic origin. With ZFNs, it has been shown that the maximal expression 
time can be limited by tagging the proteins with small molecule-controlled destabilizing 
domains to reduce enzyme-related cytotoxicity (Pruett-Miller et al. 2009). Such an approach 
may also be used with I-PpoI or other rDNA-directed nucleases if efficient cleavage at the 
rDNA would be found to threaten the viability of target cells during integration experiments. 
 
59 
 
 
6.2 INTEGRATION INTO SAFE HARBORS AND THE RIBOSOMAL DNA   
The genotoxic potential of integrating vectors has been well established to date. Developing a 
method for safe and specific gene insertion represents the Holy Grail of gene therapy, as it 
would overcome many of the safety issues and ethical problems that currently restrict the use of 
integrating vectors in gene therapy, and may therefore hamper the development of new and 
life-saving treatments.     
Of the integrating vectors available for gene therapists today, vectors based on site-specific 
nucleases are thought to hold the most useful potential for genome editing and accurate 
integration of desired sequences into predetermined loci, assuming their successful 
vectorization. As previously mentioned, however, the site-specificity of target cleavage with the 
most commonly used ZFNs is not as high as initially believed. This, together with the 
recombination of multiple donor sequences possessing or lacking homologous arms into 
cleaved sites, and the frequent introduction of unintended indel-mutations represent safety 
risks for the use of DSBs as drivers for gene addition. It remains to be seen whether the more 
recent CRISPR systems will hold their promise as a facile and versatile system for targeting 
genomic sites for cleavage, and whether their cytotoxicity profiles are better than those of the 
ZFNs or TALENs. IN-catalysed integration has not been reported to associate with cytotoxicity 
or genomic rearrangement events and it may therefore represent a safer approach for 
therapeutic gene integration, especially if efficiently targeted to a GSH. On a genome-wide 
scale, nuclease-induced gene addition can, however, be less genotoxic than that obtained with 
e.g. γRVVs due to the limited number of off-target sites in comparison to the inherently 
mutagenic nature of γRV integration.  
The genomic sites mostly targeted for transgene integration with LVV or IDLV-associated 
nucleases include the AAVS1, CCR5 and ILR2G (Table 2), but none of the most common GSH 
candidates seem to be truly trouble-free targets for disruption by transgene integration 
(Sadelain et al. 2011). rDNA is a unique environment in the nuclei of eukaryotes in terms of 
both its conserved nucleotide sequence and the nucleolar structures forming around rRNA 
genes. rDNA has been targeted for integration in both yeast and human cells with different 
methods. I-PpoI intron homing was found to occur in yeast cells following transfection of the 
natural HE gene-containing intron of Physarum polycephalum (Muscarella & Vogt 1993).  In 
addition, expressing the endonuclease in trans was able to promote so-called trans-integration 
of intron sequences where the I-PpoI ORF had been replaced by a heterologous gene (Lin & 
Vogt 1998).  Whereas these integration events were catalysed by DSB-driven HDR or NHEJ, 
integration targeting into the rDNA of human cells has also been pursued by traditional HR. 
Electroporation of homology arm-containing plasmids was reported to achieve a relative rDNA 
targeting frequency of over 50%, but the actual frequency of site-specific HR/ integration (1.1 x 
10-5) is, however, typically considered to be too low for practical purposes (Liu et al. 2007; Liu et 
al. 2012). rRNA gene-specific homology arms have also been incorporated into rAAVs to target 
vector integration into rDNA, which is a natural hotspot for rAAV integration (Nakai et al. 
2005; Wang et al. 2012; Lisowski et al. 2012). These vectors integrated into the targeted locus at a 
frequency of 23-39%, which was 8-13, or even 30 times more often than that seen for control 
vectors. However, it was also estimated that HR-specific integration into the 28S rRNA gene 
occurred in only ~2-4% (Wang et al. 2012), or in 11-17% (Lisowski et al. 2012) of mouse 
hepatocytes. The numbers of proficient ISs were low and some of the results may have been 
affected by the selection advantage conferred by the integrated transgene, complicating the 
interpretation of these results. Typical for rAAVs, concatameric insertions were present also in 
the rDNA-targeted cells. In comparison to plasmid based systems, the rAAV-approach 
nevertheless represents a more applicable system for gene delivery into many tissues. 
In this study, an absolute rDNA targeting efficiency of 2.7% was obtained in the absence of 
selection, representing a 27 fold increase to the rDNA-localization frequency of the control 
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vector. These targeted integrations were catalysed by HIV-1 IN and the transgene constructs 
contained no homology to the intended integration site. Although both the catalyst of 
integration and the cell type of this study differ from the experiments listed in Table 2, it can be 
noted that the percentages of targeted integration events reported here are similar to many of 
those previously published (Table 2). The rDNA targeting frequencies of the different methods 
described above are difficult to compare explicitly due to the dissimilarities present in the 
targeting systems, use of selection and homology arms, and in the analysis methods used. 
Nevertheless, directing integration into rDNA is feasible with different methods, although at 
relatively low efficiencies.  
An important consideration is to determine whether rDNA truly represents a sound GSH 
that can promote stable transgene expression. The studies conducted in yeast and human cells 
have revealed that functional proteins can be expressed from the rDNA locus as RNA 
polymerase I transcripts, but also from RNA polymerase II promoters, as verified in human and 
mouse cells (Lin and Vogt 1998; Lisowski et al. 2012; Liu et al. 2012; Liu et al. 2007; Muscarella 
and Vogt 1993; Wang et al. 2012). Expression levels seem to be lower for genes inserted into the 
rDNA in comparison to genes residing elsewhere in the genome, but long-term direct 
comparisons of gene expression profiles in rDNA-targeted and non-targeted human cell clones 
are still lacking. In addition to transgene expression levels, a functional validation of rDNA as a 
GSH could also include determining the expression levels of near-by cellular genes, although 
elevated amounts of rRNA molecules are unlike to lead to adverse effects, not to mention 
oncogenicity.  Nevertheless, it is possible that e.g. fusion transcripts containing sequences from 
the transgene and the rRNA gene could result in the formation of non-functional ribosomes. 
The ability of such fusion transcripts to confer an oncogenic GOF for either the transgene 
product or the rRNA molecule should be studied, although the probability for these outcomes 
seems minute. One more important aspect related to the safety of transgene integration into 
rDNA is assessing the stability of inserted sequences. According to the literature, the 
mammalian rDNA architecture is well preserved in healthy mitotic cells (Killen et al. 2009). 
Interestingly, rDNA-targeted DSBs are moved out from the nucleolus for repair in the yeast 
Saccharomyces cerevisiae (Torres-Rosell et al. 2007). This aids to suppress rDNA recombination 
during DSB repair and ensures that the integrity of this repetitive genomic locus is maintained. 
It is not known whether transient DSB foci relocalization from the nucleolus into the 
nucleoplasm is evolutionarily conserved and also occurs in mammalian cells, but it would 
certainly be a favourable event because it would ensure that no undesired recombination events 
would follow the integration of new sequences into rDNA through DSB generation. Recently it 
has been demonstrated that the chromosomal context and epigenetic mechanisms may play a 
major role in determining the efficiency of rare-cutting endonuclease-induced genome 
engineering, and that these factors account for strong position effects that are observed between 
different target cell types (Daboussi et al. 2012). A fraction of rRNA genes are active and in an 
open conformation in each cell at all times, which is an inherent advantage when considering 
efficient DSB targeting to this locus. 
The high level of ISs localizing to non-nucleolar DNA in the current study implies that there 
are other tethering factors or DNA-interaction enhancers in addition to I-PpoI that play a major 
role in determining the IS selection of the modified vectors. The efficiency of site-specific 
integration could possibly be increased by introducing mutations into the amino acids of IN 
that are important for IN-LEDGF/p75 interaction. Although integration targeting into rDNA 
was in this thesis pursued through HIV-1 IN activity, it is possible that NHEJ-catalysed 
recombination of LVV-carried transgenes could have occurred at the rDNA target site with 
vectors carrying the endonucleolytically active IN-I-PpoIH78A protein. However, true ISs hits to 
the human genome were expected to result from IN activity and were therefore required to 
begin almost directly after the LTR sequence. Any NHEJ-originated indel-mismatches to the 
genomic DNA possibly present after the LTRs would thus have eliminated a sequence read 
from the subsequent analysis steps. Also deletions in the LTR sequences are more often found 
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when IDLV integration is associated with target DNA cleavage (Gabriel et al. 2011). In the 
future, IS profiles of endonuclease-containing LVVs will be studied in depth taking advantage 
of additional methods, such as Southern blot, PCR and modified bioinformatics methods to 
resolve possible non-homologous recombination events at the I-PpoI cleavage sites. In addition, 
stable cell clones and transgenic mouse strains harboring integrated transgenes explicitly in the 
rDNA would aid to dissect the nature of transgene expression from the rRNA gene locus, and 
its value and safety as a GSH.  
Gene therapy involving therapeutic gene integration or the correction of disease-underlying 
mutations holds great promises in that it is capable of permanently curing chronic diseases, 
thereby improving the quality of life of many patients that depend on life-long medication. 
Unfortunately gene therapy involving integrating is currently not possible without an inherent 
risk for the development of adverse effects. However, the knowledge regarding specific features 
that confer a gene transfer vector either safe or unsuitable for genome modifications has 
increased immensely since the initiation of the first successful gene therapy trials, and 
researchers around the world are actively developing methods that could overcome the current 
safety concerns related to therapeutic gene integration. Some level of unpredictability will likely 
remain associated with any method aiming at targeted genome modifications, and the selection 
of favourably altered cells prior to returning them to patients will probably remain to be an 
important step in avoiding undesired adverse effects caused by mutagenic insertions. 
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7 Conclusions 
This study aimed at testing whether transgene integration can be directed towards rDNA using 
an IN-fusion protein. The protein chosen to direct IN to the desired site was the homing 
endonuclease protein I-PpoI that has natural recognition sites in rDNA, which is an interesting 
GSH candidate for therapeutic transgene integration. In addition to the aim of integration 
targeting, vector-packaged I-PpoI tested the applicability of the developed cis-packaging 
strategy for use in the nuclear delivery of dimeric nucleases, which are one of the most 
promising tools for the enhancement of site-specific transgene integration for therapeutic 
purposes. Additional IN-fusion proteins were generated to test whether other types of cytotoxic 
or inert proteins could be packaged into vector and VLP particles and delivered into cells. The 
findings of this thesis can be summarized as follows: 
 
 
1) The IN-fusion protein, or cis-packaging strategy is a feasible platform for the generation 
of protein transducing lentiviral vectors or nucleic acid free nanoparticles carrying both 
cytotoxic and inert cargo, as verified with a meganuclease, a tumor suppressor protein 
and a fluorescent marker protein, all of which retained their anticipated activity in 
transduced cells. 
 
2) IN-fusion protein-containing vectors with optimized integration proficiency can increase 
vector integration close to a predetermined site recognized by the fusion partner.   
 
3) The integration profile of IN-modified vectors did not change towards a more genotoxic 
pattern following incorporation of the IN-fusion protein. 
 
 
 
This study confirms the vast utility and surprising plasticity of modern lentiviral vectors in the 
field of gene therapy, revealing that they can be modified to integrate with new preferences, 
and also to be used to deliver desired proteins into target cell nuclei to obtain specific cellular 
responses.             
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The integration of therapeutic genes 
into the genomes of patient’s cells 
can promote long-term expression, 
which is beneficial in the treatment of 
many disorders. However, integration 
can cause insertional mutagenesis 
and lead to the emergence of severe 
adverse effects. This thesis aimed at 
developing a vector that could target 
integration into safe areas within the 
human genome. Through modifica-
tions introduced into lentivirus vec-
tors, intracellular protein delivery and 
increased integration at the aimed 
rDNA site was achieved. These find-
ings may advance safer gene therapy. 
